{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:53:46Z","timestamp":1791975226188,"version":"4.4.0"},"reference-count":607,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"3","license":[{"start":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T00:00:00Z","timestamp":1707004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073477"],"award-info":[{"award-number":["82073477"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073477"],"award-info":[{"award-number":["82073477"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Commun"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p xml:lang=\"en\">\n                    Cancer is a leading cause of death worldwide. Targeted therapies aimed at key oncogenic driver mutations in combination with chemotherapy and radiotherapy as well as immunotherapy have benefited cancer patients considerably. Tumor protein p53 (\n                    <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                    ), a crucial tumor suppressor gene encoding p53, regulates numerous downstream genes and cellular phenotypes in response to various stressors. The affected genes are involved in diverse processes, including cell cycle arrest, DNA repair, cellular senescence, metabolic homeostasis, apoptosis, and autophagy. However, accumulating recent studies have continued to reveal novel and unexpected functions of p53 in governing the fate of tumors, for example, functions in ferroptosis, immunity, the tumor microenvironment and microbiome metabolism. Among the possibilities, the evolutionary plasticity of p53 is the most controversial, partially due to the dizzying array of biological functions that have been attributed to different regulatory mechanisms of p53 signaling. Nearly 40 years after its discovery, this key tumor suppressor remains somewhat enigmatic. The intricate and diverse functions of p53 in regulating cell fate during cancer treatment are only the tip of the iceberg with respect to its equally complicated structural biology, which has been painstakingly revealed. Additionally,\n                    <jats:italic toggle=\"yes\">TP53<\/jats:italic>\n                    mutation is one of the most significant genetic alterations in cancer, contributing to rapid cancer cell growth and tumor progression. Here, we summarized recent advances that implicate altered p53 in modulating the response to various cancer therapies, including chemotherapy, radiotherapy, and immunotherapy. Furthermore, we also discussed potential strategies for targeting p53 as a therapeutic option for cancer.\n                  <\/jats:p>","DOI":"10.1002\/cac2.12520","type":"journal-article","created":{"date-parts":[[2024,2,4]],"date-time":"2024-02-04T20:45:20Z","timestamp":1707079520000},"page":"297-360","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy"],"prefix":"10.34133","volume":"44","author":[{"given":"Bin","family":"Song","sequence":"first","affiliation":[{"name":"West China Second University Hospital","place":["Chengdu, P. R. China"]},{"name":"Sichuan University","place":["Chengdu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"West China Second University Hospital","place":["Chengdu, P. R. China"]},{"name":"Sichuan University","place":["Chengdu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1419-3635","authenticated-orcid":false,"given":"Shuyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"West China Second University Hospital","place":["Chengdu, P. R. China"]},{"name":"Sichuan University","place":["Chengdu, P. R. China"]},{"name":"The Second Affiliated Hospital of Chengdu Medical College","place":["Chengdu, P. R. China"]},{"name":"China National Nuclear Corporation 416 Hospital","place":["Chengdu, P. R. China"]},{"name":"Sichuan University","place":["Chengdu, P. R. China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2024,2,4]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07943"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204040"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0290-x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaa666"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.174"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2723"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0262-1"},{"issue":"19","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1038\/sj.onc.1202200","article-title":"Mdm2 association with p53 targets its ubiquitination","volume":"17","author":"Fuchs SY","year":"1998","unstructured":"Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene. 1998;17((19)):2543\u20102547.","journal-title":"Oncogene"},{"issue":"5","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2174\/09298673113206660325","article-title":"Targeting MDM2\u2010p53 interaction for cancer therapy: Are we there yet?","volume":"21","author":"Nag S","year":"2014","unstructured":"Nag S, Zhang X, Srivenugopal KS, Wang MH, Wang W, Zhang R. Targeting MDM2\u2010p53 interaction for cancer therapy: Are we there yet? Curr Med Chem. 2014;21((5)):553\u2010574.","journal-title":"Curr Med Chem"},{"issue":"6","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0092-8674(03)00193-4","article-title":"Pirh2, a p53\u2010Induced Ubiquitin\u2010Protein Ligase, Promotes p53 Degradation","volume":"112","author":"Leng RP","year":"2003","unstructured":"Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et\u00a0al. Pirh2, a p53\u2010Induced Ubiquitin\u2010Protein Ligase, Promotes p53 Degradation. Cell. 2003;112((6)):779\u2010791.","journal-title":"Cell"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-00962-9"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-00989-y"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249648"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-022-00571-8"},{"issue":"1","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/cdd.2017.185","article-title":"Mutant p53 partners in crime","volume":"25","author":"Kim MP","year":"2018","unstructured":"Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ. 2018;25((1)):161\u2010168.","journal-title":"Cell Death Differ"},{"issue":"4","key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.tcb.2020.12.011","article-title":"p53 and Tumor Suppression: It Takes a Network","volume":"31","author":"Boutelle AM","year":"2021","unstructured":"Boutelle AM, Attardi LD. p53 and Tumor Suppression: It Takes a Network. Trends Cell Biol. 2021;31((4)):298\u2010310.","journal-title":"Trends Cell Biol"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.028"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.07.005"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.174"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.10.005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-019-0110-x"},{"issue":"5","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.3892\/ol.2017.5901","article-title":"Efficacy of recombinant human adenovirus\u2010p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial","volume":"13","author":"Xiao J","year":"2017","unstructured":"Xiao J, Zhou J, Fu M, Liang L, Deng Q, Liu X, et\u00a0al. Efficacy of recombinant human adenovirus\u2010p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial. Oncol Lett. 2017;13((5)):3676\u20103680.","journal-title":"Oncol Lett"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.04.031"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/278261a0"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(79)90293-9"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90045-7"},{"issue":"22","key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"8763","DOI":"10.1073\/pnas.86.22.8763","article-title":"Wild\u2010type p53 can inhibit oncogene\u2010mediated focus formation","volume":"86","author":"Eliyahu D","year":"1989","unstructured":"Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi\u2010Kimhi O, Oren M. Wild\u2010type p53 can inhibit oncogene\u2010mediated focus formation. Proc Natl Acad Sci U S A. 1989;86((22)):8763\u20108767.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.151"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133344"},{"issue":"6","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000919","article-title":"The tumor suppressor p53: From structures to drug discovery","volume":"2","author":"Joerger AC","year":"2010","unstructured":"Joerger AC, Fersht AR. The tumor suppressor p53: From structures to drug discovery. Cold Spring Harb Perspect Biol. 2010;2((6)):a000919.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8023157"},{"issue":"8","key":"e_1_3_2_33_2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000935","article-title":"Transcriptional regulation by p53","volume":"2","author":"Beckerman R","year":"2010","unstructured":"Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harb Perspect Biol. 2010;2((8)):a000935.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0492-45"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.04.037"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90644-R"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.12.8945"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1431692100"},{"issue":"25","key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1038\/onc.2016.518","article-title":"Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP\/TAZ","volume":"36","author":"Escoll M","year":"2017","unstructured":"Escoll M, Gargini R, Cuadrado A, Anton IM, Wandosell F. Mutant p53 oncogenic functions in cancer stem cells are regulated by WIP through YAP\/TAZ. Oncogene. 2017;36((25)):3515\u20103527.","journal-title":"Oncogene"},{"issue":"16","key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1101\/gad.301564.117","article-title":"Gain\u2010of\u2010function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression","volume":"31","author":"Yue X","year":"2017","unstructured":"Yue X, Zhang C, Zhao Y, Liu J, Lin AW, Tan VM, et\u00a0al. Gain\u2010of\u2010function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes Dev. 2017;31((16)):1641\u20101654.","journal-title":"Genes Dev"},{"issue":"6630","key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt Y","year":"1997","unstructured":"Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387((6630)):296\u2010299.","journal-title":"Nature"},{"issue":"10","key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.onc.1201459","article-title":"p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding","volume":"15","author":"Midgley CA","year":"1997","unstructured":"Midgley CA, Lane DP. p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene. 1997;15((10)):1179\u20101189.","journal-title":"Oncogene"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051426"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.180"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.03.042"},{"issue":"2","key":"e_1_3_2_46_2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001107","article-title":"Mutant p53 gain\u2010of\u2010function in cancer","volume":"2","author":"Oren M","year":"2010","unstructured":"Oren M, Rotter V. Mutant p53 gain\u2010of\u2010function in cancer. Cold Spring Harb Perspect Biol. 2010;2((2)):a001107.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020541"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.492"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.11.006"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.11.004"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.9.9.3982-3991.1989"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0593-42"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.256.5058.827"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.12.12.5581-5592.1992"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90384-B"},{"issue":"10","key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1096\/fasebj.7.10.8344492","article-title":"Dosage\u2010dependent dominance over wild\u2010type p53 of a mutant p53 isolated from nasopharyngeal carcinoma","volume":"7","author":"Sun Y","year":"1993","unstructured":"Sun Y, Dong Z, Nakamura K, Colburn NH. Dosage\u2010dependent dominance over wild\u2010type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. Faseb J. 1993;7((10)):944\u2010950.","journal-title":"Faseb J"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90113-S"},{"issue":"7","key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/emboj\/17.7.1847","article-title":"Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations","volume":"17","author":"Brachmann RK","year":"1998","unstructured":"Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD. Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. Embo J. 1998;17((7)):1847\u20101859.","journal-title":"Embo J"},{"issue":"14","key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/nar\/21.14.3167","article-title":"Activation of the cryptic DNA binding function of mutant forms of p53","volume":"21","author":"Hupp TR","year":"1993","unstructured":"Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res. 1993;21((14)):3167\u20103174.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-632"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90165-5"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.151"},{"issue":"14","key":"e_1_3_2_63_2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1093\/jnci\/88.14.956","article-title":"UCN\u201001: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53","volume":"88","author":"Wang Q","year":"1996","unstructured":"Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. UCN\u201001: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst. 1996;88((14)):956\u2010965.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0697-639"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5449.2507"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1835733100"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjaa040"},{"issue":"5","key":"e_1_3_2_68_2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR\u2010246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang Q","year":"2018","unstructured":"Zhang Q, Bykov VJN, Wiman KG, Zawacka\u2010Pankau J. APR\u2010246 reactivates mutant p53 by targeting cysteines 124 and 277. Cell Death Dis. 2018;9((5)):439.","journal-title":"Cell Death Dis"},{"issue":"14","key":"e_1_3_2_69_2","first-page":"3893","article-title":"Mechanisms of action of arsenic trioxide","volume":"62","author":"Miller WH","year":"2002","unstructured":"Miller WH Jr., Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62((14)):3893\u20103903.","journal-title":"Cancer Res"},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1756-8722-3-28","article-title":"Basic mechanisms of arsenic trioxide (ATO)\u2010induced apoptosis in human leukemia (HL\u201060) cells","volume":"3","author":"Yedjou C","year":"2010","unstructured":"Yedjou C, Tchounwou P, Jenkins J, McMurray R. Basic mechanisms of arsenic trioxide (ATO)\u2010induced apoptosis in human leukemia (HL\u201060) cells. J Hematol Oncol. 2010;3:28.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.11.013"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn9155"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi026635n"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjy070"},{"issue":"1","key":"e_1_3_2_75_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41392-020-00336-y","article-title":"Gut microbiome alters functions of mutant p53 to promote tumorigenesis","volume":"5","author":"Lau HCH","year":"2020","unstructured":"Lau HCH, Yu J. Gut microbiome alters functions of mutant p53 to promote tumorigenesis. Signal Transduct Target Ther. 2020;5((1)):232.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.04.026"},{"issue":"7545","key":"e_1_3_2_77_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53\u2010mediated activity during tumour suppression","volume":"520","author":"Jiang L","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et\u00a0al. Ferroptosis as a p53\u2010mediated activity during tumour suppression. Nature. 2015;520((7545)):57\u201062.","journal-title":"Nature"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.10.004"},{"issue":"6381","key":"e_1_3_2_79_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane DP","year":"1992","unstructured":"Lane DP. Cancer. p53, guardian of the genome. Nature.1992;358((6381)):15\u201016.","journal-title":"Nature"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188556"},{"key":"e_1_3_2_81_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semcancer.2021.03.010","article-title":"The complexity of p53\u2010mediated metabolic regulation in tumor suppression","volume":"85","author":"Liu Y","year":"2021","unstructured":"Liu Y, Gu W. The complexity of p53\u2010mediated metabolic regulation in tumor suppression. Semin Cancer Biol. 2021;85:4\u201032.","journal-title":"Semin Cancer Biol"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.021"},{"issue":"5","key":"e_1_3_2_83_2","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001032","article-title":"Single\u2010nucleotide polymorphisms in the p53 signaling pathway","volume":"2","author":"Grochola LF","year":"2010","unstructured":"Grochola LF, Zeron\u2010Medina J, M\u00e9riaux S, Bond GL. Single\u2010nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol. 2010;2((5)):a001032.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9","key":"e_1_3_2_84_2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4161\/epi.6.9.16683","article-title":"Transcriptional and epigenetic regulation of the p53 tumor suppressor gene","volume":"6","author":"Salda\u00f1a\u2010Meyer R","year":"2011","unstructured":"Salda\u00f1a\u2010Meyer R, Recillas\u2010Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. Epigenetics. 2011;6((9)):1068\u20101077.","journal-title":"Epigenetics"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10090288"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M407601200"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1432-1327.2001.02227.x"},{"issue":"2","key":"e_1_3_2_88_2","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbcan.2017.08.001","article-title":"p53 stability is regulated by diverse deubiquitinating enzymes","volume":"1868","author":"Kwon SK","year":"2017","unstructured":"Kwon SK, Saindane M, Baek KH. p53 stability is regulated by diverse deubiquitinating enzymes. Biochim Biophys Acta Rev Cancer. 2017;1868((2)):404\u2010411.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.04.050"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1455"},{"issue":"11","key":"e_1_3_2_91_2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.molmed.2010.09.002","article-title":"p53 post\u2010translational modification: Deregulated in tumorigenesis","volume":"16","author":"Dai C","year":"2010","unstructured":"Dai C, Gu W. p53 post\u2010translational modification: Deregulated in tumorigenesis. Trends Mol Med. 2010;16((11)):528\u2010536.","journal-title":"Trends Mol Med"},{"issue":"1","key":"e_1_3_2_92_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1074\/mcp.M113.030254","article-title":"Extensive post\u2010translational modification of active and inactivated forms of endogenous p53","volume":"13","author":"DeHart CJ","year":"2014","unstructured":"DeHart CJ, Chahal JS, Flint SJ, Perlman DH. Extensive post\u2010translational modification of active and inactivated forms of endogenous p53. Mol Cell Proteomics. 2014;13((1)):1\u201017.","journal-title":"Mol Cell Proteomics"},{"issue":"5","key":"e_1_3_2_93_2","doi-asserted-by":"crossref","first-page":"672","DOI":"10.7150\/ijbs.4283","article-title":"Surf the post\u2010translational modification network of p53 regulation","volume":"8","author":"Gu B","year":"2012","unstructured":"Gu B, Zhu WG. Surf the post\u2010translational modification network of p53 regulation. Int J Biol Sci. 2012;8((5)):672\u2010684.","journal-title":"Int J Biol Sci"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M410233200"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.12.18.2831"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku501"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80416-X"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.24.13777"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb715"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb714"},{"key":"e_1_3_2_101_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-012-1254-4"},{"key":"e_1_3_2_102_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2007.10"},{"key":"e_1_3_2_103_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/0470862637.ch14","article-title":"Dynamics of the p53 acetylation pathway","volume":"259","author":"Gu W","year":"2004","unstructured":"Gu W, Luo J, Brooks CL, Nikolaev AY, Li M. Dynamics of the p53 acetylation pathway. Novartis Found Symp. 2004;259:197\u2010205.","journal-title":"Novartis Found Symp"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80304-9"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1038\/42981"},{"issue":"3","key":"e_1_3_2_106_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrc1818","article-title":"ASPP [corrected] and cancer","volume":"6","author":"Trigiante G","year":"2006","unstructured":"Trigiante G, Lu X. ASPP [corrected] and cancer. Nat Rev Cancer. 2006;6((3)):217\u2010226.","journal-title":"Nat Rev Cancer"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2011.04.012"},{"issue":"6","key":"e_1_3_2_108_2","article-title":"Posttranslational modification of p53: Cooperative integrators of function","volume":"1","author":"Meek DW","year":"2009","unstructured":"Meek DW, Anderson CW. Posttranslational modification of p53: Cooperative integrators of function. Cold Spring Harb Perspect Biol. 2009;1((6)):a000950.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"32","key":"e_1_3_2_109_2","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1021\/acs.biochem.9b00333","article-title":"Tumor Suppressor p53\u2010Mediated Structural Reorganization of the Transcriptional Coactivator p300","volume":"58","author":"Ghosh R","year":"2019","unstructured":"Ghosh R, Kaypee S, Shasmal M, Kundu TK, Roy S, Sengupta J. Tumor Suppressor p53\u2010Mediated Structural Reorganization of the Transcriptional Coactivator p300. Biochemistry. 2019;58((32)):3434\u20103443.","journal-title":"Biochemistry"},{"issue":"3","key":"e_1_3_2_110_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/bfgp\/ell028","article-title":"Histone acetylation in gene regulation","volume":"5","author":"Verdone L","year":"2006","unstructured":"Verdone L, Agricola E, Caserta M, Di Mauro E. Histone acetylation in gene regulation. Brief Funct Genomic Proteomic. 2006;5((3)):209\u2010221.","journal-title":"Brief Funct Genomic Proteomic"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.5b01210"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)86524-9"},{"issue":"1","key":"e_1_3_2_113_2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1083\/jcb.97.1.258","article-title":"Chlamydomonas alpha\u2010tubulin is posttranslationally modified in the flagella during flagellar assembly","volume":"97","author":"L'Hernault SW","year":"1983","unstructured":"L'Hernault SW, Rosenbaum JL. Chlamydomonas alpha\u2010tubulin is posttranslationally modified in the flagella during flagellar assembly. J Cell Biol. 1983;97((1)):258\u2010263.","journal-title":"J Cell Biol"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1038\/42972"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3931"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-018-0081-3"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80521-8"},{"issue":"2","key":"e_1_3_2_118_2","first-page":"55","article-title":"Acetylation and phosphorylation of the carboxy\u2010terminal domain of p53: Regulative significance","volume":"10","author":"Chiarugi V","year":"1998","unstructured":"Chiarugi V, Cinelli M, Magnelli L. Acetylation and phosphorylation of the carboxy\u2010terminal domain of p53: Regulative significance. Oncol Res. 1998;10((2)):55\u201057.","journal-title":"Oncol Res"},{"issue":"1","key":"e_1_3_2_119_2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11033-019-05141-7","article-title":"The role of acetylation sites in the regulation of p53 activity","volume":"47","author":"Wang Y","year":"2020","unstructured":"Wang Y, Chen Y, Chen Q, Zhang X, Wang H, Wang Z, et\u00a0al. The role of acetylation sites in the regulation of p53 activity. Mol Biol Rep. 2020;47((1)):381\u2010391.","journal-title":"Mol Biol Rep"},{"issue":"6","key":"e_1_3_2_120_2","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.chembiol.2018.03.010","article-title":"A Designed Peptide Targets Two Types of Modifications of p53 with Anti\u2010cancer Activity","volume":"25","author":"Liang L","year":"2018","unstructured":"Liang L, Wang H, Shi H, Li Z, Yao H, Bu Z, et\u00a0al. A Designed Peptide Targets Two Types of Modifications of p53 with Anti\u2010cancer Activity. Cell Chem Biol. 2018;25((6)):761\u2010774. e5.","journal-title":"Cell Chem Biol"},{"issue":"7","key":"e_1_3_2_121_2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41389-018-0063-5","article-title":"A dual role of miR\u201022 modulated by RelA\/p65 in resensitizing fulvestrant\u2010resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382","volume":"7","author":"Wang B","year":"2018","unstructured":"Wang B, Li D, Filkowski J, Rodriguez\u2010Juarez R, Storozynsky Q, Malach M, et\u00a0al. A dual role of miR\u201022 modulated by RelA\/p65 in resensitizing fulvestrant\u2010resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382. Oncogenesis. 2018;7((7)):54.","journal-title":"Oncogenesis"},{"issue":"52","key":"e_1_3_2_122_2","doi-asserted-by":"crossref","first-page":"50607","DOI":"10.1074\/jbc.C200578200","article-title":"Acetylation of p53 inhibits its ubiquitination by Mdm2","volume":"277","author":"Li M","year":"2002","unstructured":"Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem. 2002;277((52)):50607\u201050611.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjz060"},{"issue":"21","key":"e_1_3_2_124_2","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1038\/sj.onc.1201818","article-title":"Functional interplay between p53 and E2F through co\u2010activator p300","volume":"16","author":"Lee CW","year":"1998","unstructured":"Lee CW, S\u00f8rensen TS, Shikama N, La Thangue NB. Functional interplay between p53 and E2F through co\u2010activator p300. Oncogene. 1998;16((21)):2695\u20102710.","journal-title":"Oncogene"},{"key":"e_1_3_2_125_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1080386"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1062961"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.1038\/35053110"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abi6684"},{"issue":"3","key":"e_1_3_2_129_2","first-page":"203","article-title":"Post\u2010translational modification of p53","volume":"5","author":"Meek DW","year":"1994","unstructured":"Meek DW. Post\u2010translational modification of p53. Semin Cancer Biol. 1994;5((3)):203\u2010210.","journal-title":"Semin Cancer Biol"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200512059"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.026096"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.01.011"},{"issue":"23","key":"e_1_3_2_133_2","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.3390\/cells11233825","article-title":"Insights into Regulators of p53 Acetylation","volume":"11","author":"Nagasaka M","year":"2022","unstructured":"Nagasaka M, Miyajima C, Aoki H, Aoyama M, Morishita D, Inoue Y, et\u00a0al. Insights into Regulators of p53 Acetylation. Cells. 2022;11((23)):3825.","journal-title":"Cells"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.04.015"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2017.07.002"},{"key":"e_1_3_2_136_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1802"},{"issue":"4","key":"e_1_3_2_137_2","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.molcel.2011.08.007","article-title":"The methyltransferase Set7\/9 (Setd7) is dispensable for the p53\u2010mediated DNA damage response in vivo","volume":"43","author":"Campaner S","year":"2011","unstructured":"Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, et\u00a0al. The methyltransferase Set7\/9 (Setd7) is dispensable for the p53\u2010mediated DNA damage response in vivo. Mol Cell. 2011;43((4)):681\u2010688.","journal-title":"Mol Cell"},{"issue":"2","key":"e_1_3_2_138_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41419-019-1328-4","article-title":"SETD3 is a positive regulator of DNA\u2010damage\u2010induced apoptosis","volume":"10","author":"Abaev\u2010Schneiderman E","year":"2019","unstructured":"Abaev\u2010Schneiderman E, Admoni\u2010Elisha L, Levy D. SETD3 is a positive regulator of DNA\u2010damage\u2010induced apoptosis. Cell Death Dis. 2019;10((2)):74.","journal-title":"Cell Death Dis"},{"key":"e_1_3_2_139_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03117"},{"key":"e_1_3_2_140_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13008-018-0036-2","article-title":"Protein arginine methylation: An emerging regulator of the cell cycle","volume":"13","author":"Raposo AE","year":"2018","unstructured":"Raposo AE, Piller SC. Protein arginine methylation: An emerging regulator of the cell cycle. Cell Div. 2018;13:3.","journal-title":"Cell Div"},{"key":"e_1_3_2_141_2","doi-asserted-by":"publisher","DOI":"10.2217\/epi-2017-0052"},{"key":"e_1_3_2_142_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0625"},{"key":"e_1_3_2_143_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1208-1389"},{"key":"e_1_3_2_144_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2502"},{"issue":"7119","key":"e_1_3_2_145_2","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature05287","article-title":"Repression of p53 activity by Smyd2\u2010mediated methylation","volume":"444","author":"Huang J","year":"2006","unstructured":"Huang J, Perez\u2010Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et\u00a0al. Repression of p53 activity by Smyd2\u2010mediated methylation. Nature. 2006;444((7119)):629\u2010632.","journal-title":"Nature"},{"key":"e_1_3_2_146_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03117"},{"key":"e_1_3_2_147_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.07.012"},{"issue":"7158","key":"e_1_3_2_148_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature06092","article-title":"p53 is regulated by the lysine demethylase LSD1","volume":"449","author":"Huang J","year":"2007","unstructured":"Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, et\u00a0al. p53 is regulated by the lysine demethylase LSD1. Nature. 2007;449((7158)):105\u2010108.","journal-title":"Nature"},{"key":"e_1_3_2_149_2","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13524"},{"issue":"3","key":"e_1_3_2_150_2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4161\/cc.7.3.5328","article-title":"Protective mechanisms of p53\u2010p21\u2010pRb proteins against DNA damage\u2010induced cell death","volume":"7","author":"Garner E","year":"2008","unstructured":"Garner E, Raj K. Protective mechanisms of p53\u2010p21\u2010pRb proteins against DNA damage\u2010induced cell death. Cell Cycle. 2008;7((3)):277\u2010282.","journal-title":"Cell Cycle"},{"key":"e_1_3_2_151_2","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-14-0385"},{"key":"e_1_3_2_152_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2009.01.002"},{"key":"e_1_3_2_153_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(01)00349-5"},{"key":"e_1_3_2_154_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e12-10-0771"},{"key":"e_1_3_2_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(03)00050-9"},{"key":"e_1_3_2_156_2","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2015.6556"},{"key":"e_1_3_2_157_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2017.225"},{"key":"e_1_3_2_158_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.70.1.503"},{"key":"e_1_3_2_159_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.105"},{"key":"e_1_3_2_160_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1127085"},{"key":"e_1_3_2_161_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90384-3"},{"key":"e_1_3_2_162_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.22.8458-8467.2000"},{"key":"e_1_3_2_163_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1091362"},{"key":"e_1_3_2_164_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature07986"},{"key":"e_1_3_2_165_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.01.020"},{"issue":"1","key":"e_1_3_2_166_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/jmcb\/mjx004","article-title":"Mdm proteins: Critical regulators of embry ogenesis and homeostasis","volume":"9","author":"Moyer SM","year":"2017","unstructured":"Moyer SM, Larsson CA, Lozano G. Mdm proteins: Critical regulators of embry ogenesis and homeostasis. J Mol Cell Biol. 2017;9((1)):16\u201025.","journal-title":"J Mol Cell Biol"},{"key":"e_1_3_2_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101157"},{"key":"e_1_3_2_168_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.021"},{"key":"e_1_3_2_169_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M501574200"},{"key":"e_1_3_2_170_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02514"},{"issue":"16","key":"e_1_3_2_171_2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.4161\/cc.7.16.6422","article-title":"p53\u2010Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53","volume":"7","author":"Carter S","year":"2008","unstructured":"Carter S, Vousden KH. p53\u2010Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle. 2008;7((16)):2519\u20102528.","journal-title":"Cell Cycle"},{"key":"e_1_3_2_172_2","doi-asserted-by":"publisher","DOI":"10.1038\/embor.2008.183"},{"issue":"9","key":"e_1_3_2_173_2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/emboj.2009.83","article-title":"Crosstalk between sumoylation and acetylation regulates p53\u2010dependent chromatin transcription and DNA binding","volume":"28","author":"Wu SY","year":"2009","unstructured":"Wu SY, Chiang CM. Crosstalk between sumoylation and acetylation regulates p53\u2010dependent chromatin transcription and DNA binding. Embo j. 2009;28((9)):1246\u20101259.","journal-title":"Embo j"},{"key":"e_1_3_2_174_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.06.016"},{"key":"e_1_3_2_175_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M609001200"},{"key":"e_1_3_2_176_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1470"},{"issue":"5","key":"e_1_3_2_177_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.bbagrm.2010.02.005","article-title":"Modulation of transcription factor function by O\u2010GlcNAc modification","volume":"1799","author":"Ozcan S","year":"2010","unstructured":"Ozcan S, Andrali SS, Cantrell JE. Modulation of transcription factor function by O\u2010GlcNAc modification. Biochim Biophys Acta. 2010;1799((5\u20106)):353\u2010364.","journal-title":"Biochim Biophys Acta"},{"key":"e_1_3_2_178_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.06.108"},{"issue":"6","key":"e_1_3_2_179_2","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/s41418-018-0072-0","article-title":"Oncogene\u2010induced senescence mediated by c\u2010Myc requires USP10 dependent deubiquitination and stabilization of p14ARF","volume":"25","author":"Ko A","year":"2018","unstructured":"Ko A, Han SY, Choi CH, Cho H, Lee MS, Kim SY, et\u00a0al. Oncogene\u2010induced senescence mediated by c\u2010Myc requires USP10 dependent deubiquitination and stabilization of p14ARF. Cell Death Differ. 2018;25((6)):1050\u20101062.","journal-title":"Cell Death Differ"},{"key":"e_1_3_2_180_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.01.034"},{"issue":"3","key":"e_1_3_2_181_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41419-019-1463-y","article-title":"p53 \u03b2\u2010hydroxybutyrylation attenuates p53 activity","volume":"10","author":"Liu K","year":"2019","unstructured":"Liu K, Li F, Sun Q, Lin N, Han H, You K, et\u00a0al. p53 \u03b2\u2010hydroxybutyrylation attenuates p53 activity. Cell Death Dis. 2019;10((3)):243.","journal-title":"Cell Death Dis"},{"key":"e_1_3_2_182_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0542-3"},{"key":"e_1_3_2_183_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1293"},{"key":"e_1_3_2_184_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.07.010"},{"key":"e_1_3_2_185_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1218351"},{"key":"e_1_3_2_186_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973635"},{"key":"e_1_3_2_187_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3452"},{"key":"e_1_3_2_188_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1909550116"},{"issue":"22","key":"e_1_3_2_189_2","doi-asserted-by":"crossref","first-page":"10097","DOI":"10.1128\/MCB.25.22.10097-10110.2005","article-title":"Tumor\u2010derived p53 mutants induce NF\u2010kappaB2 gene expression","volume":"25","author":"Scian MJ","year":"2005","unstructured":"Scian MJ, Stagliano KE, Anderson MA, Hassan S, Bowman M, Miles MF, et\u00a0al. Tumor\u2010derived p53 mutants induce NF\u2010kappaB2 gene expression. Mol Cell Biol. 2005;25((22)):10097\u201010110.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"e_1_3_2_190_2","doi-asserted-by":"crossref","DOI":"10.15252\/msb.202110588","article-title":"Time\u2010series transcriptomics and proteomics reveal alternative modes to decode p53 oscillations","volume":"18","author":"Jim\u00e9nez A","year":"2022","unstructured":"Jim\u00e9nez A, Lu D, Kalocsay M, Berberich MJ, Balbi P, Jambhekar A, et\u00a0al. Time\u2010series transcriptomics and proteomics reveal alternative modes to decode p53 oscillations. Molecular systems biology. 2022;18((3)):e10588.","journal-title":"Molecular systems biology"},{"key":"e_1_3_2_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2016.03.006"},{"issue":"1","key":"e_1_3_2_192_2","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41467-021-21145-z","article-title":"p53 dynamics vary between tissues and are linked with radiation sensitivity","volume":"12","author":"Stewart\u2010Ornstein J","year":"2021","unstructured":"Stewart\u2010Ornstein J, Iwamoto Y, Miller MA, Prytyskach MA, Ferretti S, Holzer P, et\u00a0al. p53 dynamics vary between tissues and are linked with radiation sensitivity. Nat Commun. 2021;12((1)):898.","journal-title":"Nat Commun"},{"issue":"4","key":"e_1_3_2_193_2","doi-asserted-by":"crossref","DOI":"10.4161\/23723548.2014.969136","article-title":"p53 isoforms change p53 paradigm","volume":"1","author":"Bourdon JC","year":"2014","unstructured":"Bourdon JC. p53 isoforms change p53 paradigm. Mol Cell Oncol. 2014;1((4)):e969136.","journal-title":"Mol Cell Oncol"},{"key":"e_1_3_2_194_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12912"},{"key":"e_1_3_2_195_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2693"},{"key":"e_1_3_2_196_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12634"},{"key":"e_1_3_2_197_2","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.759154","article-title":"TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer","volume":"9","author":"Zhang Z","year":"2021","unstructured":"Zhang Z, Hao R, Guo Q, Zhang S, Wang X. TP53 Mutation Infers a Poor Prognosis and Is Correlated to Immunocytes Infiltration in Breast Cancer. Front Cell Dev Biol. 2021;9:759154.","journal-title":"Front Cell Dev Biol"},{"key":"e_1_3_2_198_2","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22552"},{"key":"e_1_3_2_199_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2179"},{"key":"e_1_3_2_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2018.05.001"},{"key":"e_1_3_2_201_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13164088"},{"issue":"11","key":"e_1_3_2_202_2","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: From molecular mechanism to therapeutic modulation","volume":"13","author":"Chen X","year":"2022","unstructured":"Chen X, Zhang T, Su W, Dou Z, Zhao D, Jin X, et\u00a0al. Mutant p53 in cancer: From molecular mechanism to therapeutic modulation. Cell Death Dis. 2022;13((11)):974.","journal-title":"Cell Death Dis"},{"key":"e_1_3_2_203_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.595187"},{"key":"e_1_3_2_204_2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.17929","article-title":"TP53 exon\u20106 truncating mutations produce separation of function isoforms with pro\u2010tumorigenic functions","volume":"5","author":"Shirole NH","year":"2016","unstructured":"Shirole NH, Pal D, Kastenhuber ER, Senturk S, Boroda J, Pisterzi P, et\u00a0al. TP53 exon\u20106 truncating mutations produce separation of function isoforms with pro\u2010tumorigenic functions. Elife. 2016;5:e17929.","journal-title":"Elife"},{"issue":"4","key":"e_1_3_2_205_2","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a003921","article-title":"From uncertainty to pathogenicity: Clinical and functional interrogation of a rare TP53 in\u2010frame deletion","volume":"5","author":"Quinn EA","year":"2019","unstructured":"Quinn EA, Maciaszek JL, Pinto EM, Phillips AH, Berdy D, Khandwala M, et\u00a0al. From uncertainty to pathogenicity: Clinical and functional interrogation of a rare TP53 in\u2010frame deletion. Cold Spring Harb Mol Case Stud. 2019;5((4)):a003921.","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"e_1_3_2_206_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-009-0657-2"},{"key":"e_1_3_2_207_2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.3389\/fonc.2020.01460","article-title":"Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy","volume":"10","author":"Chasov V","year":"2020","unstructured":"Chasov V, Mirgayazova R, Zmievskaya E, Khadiullina R, Valiullina A, Stephenson Clarke J, et\u00a0al. Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy. Front Oncol. 2020;10:1460.","journal-title":"Front Oncol"},{"key":"e_1_3_2_208_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.21.5.1874-1887.2001"},{"issue":"21","key":"e_1_3_2_209_2","doi-asserted-by":"crossref","first-page":"18817","DOI":"10.1074\/jbc.M201405200","article-title":"Physical interaction with human tumor\u2010derived p53 mutants inhibits p63 activities","volume":"277","author":"Strano S","year":"2002","unstructured":"Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, et\u00a0al. Physical interaction with human tumor\u2010derived p53 mutants inhibits p63 activities. J Biol Chem. 2002;277((21)):18817\u201018826.","journal-title":"J Biol Chem"},{"issue":"46","key":"e_1_3_2_210_2","doi-asserted-by":"crossref","first-page":"E6349","DOI":"10.1073\/pnas.1510043112","article-title":"Amino\u2010terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis","volume":"112","author":"Phang BH","year":"2015","unstructured":"Phang BH, Othman R, Bougeard G, Chia RH, Frebourg T, Tang CL, et\u00a0al. Amino\u2010terminal p53 mutations lead to expression of apoptosis proficient p47 and prognosticate better survival, but predispose to tumorigenesis. Proc Natl Acad Sci U S A. 2015;112((46)):E6349\u2010E6358.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_211_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.18.7.3692"},{"key":"e_1_3_2_212_2","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2147\/OTT.S229065","article-title":"P53 Mutant p53N236S Regulates Cancer\u2010Associated Fibroblasts Properties Through Stat3 Pathway","volume":"13","author":"Liu Q","year":"2020","unstructured":"Liu Q, Yu B, Tian Y, Dan J, Luo Y, Wu X. P53 Mutant p53N236S Regulates Cancer\u2010Associated Fibroblasts Properties Through Stat3 Pathway. Onco Targets Ther. 2020;13:1355\u20101363.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"e_1_3_2_213_2","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1038\/s41598-017-02831-9","article-title":"Human papilloma virus E7 oncoprotein abrogates the p53\u2010p21\u2010DREAM pathway","volume":"7","author":"Fischer M","year":"2017","unstructured":"Fischer M, Uxa S, Stanko C, Magin TM, Engeland K. Human papilloma virus E7 oncoprotein abrogates the p53\u2010p21\u2010DREAM pathway. Sci Rep. 2017;7((1)):2603.","journal-title":"Sci Rep"},{"key":"e_1_3_2_214_2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.canlet.2019.10.046","article-title":"A novel small\u2010molecule inhibitor of the human papillomavirus E6\u2010p53 interaction that reactivates p53 function and blocks cancer cells growth","volume":"470","author":"Celegato M","year":"2020","unstructured":"Celegato M, Messa L, Goracci L, Mercorelli B, Bertagnin C, Spyrakis F, et\u00a0al. A novel small\u2010molecule inhibitor of the human papillomavirus E6\u2010p53 interaction that reactivates p53 function and blocks cancer cells growth. Cancer Lett. 2020;470:115\u2010125.","journal-title":"Cancer Lett"},{"key":"e_1_3_2_215_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.002"},{"key":"e_1_3_2_216_2","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14602"},{"key":"e_1_3_2_217_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a023614"},{"key":"e_1_3_2_218_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.109"},{"key":"e_1_3_2_219_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1905840"},{"key":"e_1_3_2_220_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2010.07676.x"},{"key":"e_1_3_2_221_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205803"},{"key":"e_1_3_2_222_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210302"},{"key":"e_1_3_2_223_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1633803100"},{"key":"e_1_3_2_224_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.190678.112"},{"key":"e_1_3_2_225_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.08.013"},{"issue":"1","key":"e_1_3_2_226_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1039\/B911416E","article-title":"Transcriptional control of the proliferation cluster by the tumor suppressor p53","volume":"6","author":"Brosh R","year":"2010","unstructured":"Brosh R, Rotter V. Transcriptional control of the proliferation cluster by the tumor suppressor p53. Mol Biosyst. 2010;6((1)):17\u201029.","journal-title":"Mol Biosyst"},{"issue":"2","key":"e_1_3_2_227_2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.15252\/embr.201540488","article-title":"YAP enhances the pro\u2010proliferative transcriptional activity of mutant p53 proteins","volume":"17","author":"Di Agostino S","year":"2016","unstructured":"Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, et\u00a0al. YAP enhances the pro\u2010proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016;17((2)):188\u2010201.","journal-title":"EMBO Rep"},{"issue":"5","key":"e_1_3_2_228_2","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1172\/JCI87724","article-title":"Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication","volume":"127","author":"Singh S","year":"2017","unstructured":"Singh S, Vaughan CA, Frum RA, Grossman SR, Deb S, Palit Deb S. Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication. J Clin Invest. 2017;127((5)):1839\u20101855.","journal-title":"J Clin Invest"},{"issue":"1","key":"e_1_3_2_229_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13059-017-1368-y","article-title":"The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53\/YAP\/TEAD transcription\u2010competent complex","volume":"18","author":"Verduci L","year":"2017","unstructured":"Verduci L, Ferraiuolo M, Sacconi A, Ganci F, Vitale J, Colombo T, et\u00a0al. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53\/YAP\/TEAD transcription\u2010competent complex. Genome Biol. 2017;18((1)):237.","journal-title":"Genome Biol"},{"key":"e_1_3_2_230_2","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.97"},{"key":"e_1_3_2_231_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.07.004"},{"issue":"7568","key":"e_1_3_2_232_2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nature15251","article-title":"Gain\u2010of\u2010function p53 mutants co\u2010opt chromatin pathways to drive cancer growth","volume":"525","author":"Zhu J","year":"2015","unstructured":"Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, et\u00a0al. Gain\u2010of\u2010function p53 mutants co\u2010opt chromatin pathways to drive cancer growth. Nature. 2015;525((7568)):206\u2010211.","journal-title":"Nature"},{"key":"e_1_3_2_233_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201009059"},{"key":"e_1_3_2_234_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0136"},{"key":"e_1_3_2_235_2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.10727"},{"key":"e_1_3_2_236_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.334"},{"issue":"2","key":"e_1_3_2_237_2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/cdd.2010.94","article-title":"Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial\u2010mesenchymal transition in immortalized prostate cells","volume":"18","author":"Kogan\u2010Sakin I","year":"2011","unstructured":"Kogan\u2010Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, et\u00a0al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial\u2010mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2011;18((2)):271\u2010281.","journal-title":"Cell Death Differ"},{"key":"e_1_3_2_238_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.039"},{"key":"e_1_3_2_239_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.11.026"},{"key":"e_1_3_2_240_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.148"},{"issue":"1","key":"e_1_3_2_241_2","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1038\/s41467-018-07339-y","article-title":"Mutant p53s generate pro\u2010invasive niches by influencing exosome podocalyxin levels","volume":"9","author":"Novo D","year":"2018","unstructured":"Novo D, Heath N, Mitchell L, Caligiuri G, MacFarlane A, Reijmer D, et\u00a0al. Mutant p53s generate pro\u2010invasive niches by influencing exosome podocalyxin levels. Nat Commun. 2018;9((1)):5069.","journal-title":"Nat Commun"},{"key":"e_1_3_2_242_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.01.066"},{"key":"e_1_3_2_243_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.304972.117"},{"key":"e_1_3_2_244_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1404139111"},{"key":"e_1_3_2_245_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23400"},{"key":"e_1_3_2_246_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.5166"},{"key":"e_1_3_2_247_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.00-0128com"},{"key":"e_1_3_2_248_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.04.023"},{"key":"e_1_3_2_249_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1571"},{"key":"e_1_3_2_250_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2587"},{"issue":"11","key":"e_1_3_2_251_2","doi-asserted-by":"crossref","first-page":"e1220","DOI":"10.1073\/pnas.1416318112","article-title":"Proteome\u2010wide analysis of mutant p53 targets in breast cancer identifies new levels of gain\u2010of\u2010function that influence PARP, PCNA, and MCM4","volume":"112","author":"Polotskaia A","year":"2015","unstructured":"Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, et\u00a0al. Proteome\u2010wide analysis of mutant p53 targets in breast cancer identifies new levels of gain\u2010of\u2010function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci U S A. 2015;112((11)):e1220\u2010e1229.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"e_1_3_2_252_2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1073\/pnas.0812096106","article-title":"TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity","volume":"106","author":"Tomasini R","year":"2009","unstructured":"Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Rufini A, et\u00a0al. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci U S A. 2009;106((3)):797\u2010802.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"e_1_3_2_253_2","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1038\/s41467-018-05368-1","article-title":"Genomic instability in mutant p53 cancer cells upon entotic engulfment","volume":"9","author":"Mackay HL","year":"2018","unstructured":"Mackay HL, Moore D, Hall C, Birkbak NJ, Jamal\u2010Hanjani M, Karim SA, et\u00a0al. Genomic instability in mutant p53 cancer cells upon entotic engulfment. Nat Commun. 2018;9((1)):3070.","journal-title":"Nat Commun"},{"key":"e_1_3_2_254_2","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a026203"},{"key":"e_1_3_2_255_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.57"},{"key":"e_1_3_2_256_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.04.001"},{"key":"e_1_3_2_257_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0060-8"},{"key":"e_1_3_2_258_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1391"},{"key":"e_1_3_2_259_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2018.06.001"},{"key":"e_1_3_2_260_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1126863"},{"key":"e_1_3_2_261_2","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1038\/ncomms3935","article-title":"Tumour\u2010associated mutant p53 drives the Warburg effect","volume":"4","author":"Zhang C","year":"2013","unstructured":"Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, et\u00a0al. Tumour\u2010associated mutant p53 drives the Warburg effect. Nat Commun. 2013;4:2935.","journal-title":"Nat Commun"},{"issue":"36","key":"e_1_3_2_262_2","first-page":"22776","article-title":"Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53","volume":"272","author":"Mathupala SP","year":"1997","unstructured":"Mathupala SP, Heese C, Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J Biol Chem. 1997;272((36)):22776\u201022780.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_263_2","doi-asserted-by":"publisher","DOI":"10.1002\/iub.1534"},{"issue":"1","key":"e_1_3_2_264_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cell.2011.12.017","article-title":"Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway","volume":"148","author":"Freed\u2010Pastor WA","year":"2012","unstructured":"Freed\u2010Pastor WA, Mizuno H, Zhao X, Langer\u00f8d A, Moon SH, Rodriguez\u2010Barrueco R, et\u00a0al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148((1\u20102)):244\u2010258.","journal-title":"Cell"},{"key":"e_1_3_2_265_2","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1038\/ncomms8389","article-title":"Regulation of nucleotide metabolism by mutant p53 contributes to its gain\u2010of\u2010function activities","volume":"6","author":"Kollareddy M","year":"2015","unstructured":"Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, et\u00a0al. Regulation of nucleotide metabolism by mutant p53 contributes to its gain\u2010of\u2010function activities. Nat Commun. 2015;6:7389.","journal-title":"Nat Commun"},{"key":"e_1_3_2_266_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.309062.117"},{"key":"e_1_3_2_267_2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34701","article-title":"A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models","volume":"7","author":"Zhao Y","year":"2018","unstructured":"Zhao Y, Wu L, Yue X, Zhang C, Wang J, Li J, et\u00a0al. A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. Elife. 2018;7:e34701.","journal-title":"Elife"},{"issue":"7","key":"e_1_3_2_268_2","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/jmcb\/mjz052","article-title":"Common genetic variants in the TP53 pathway and their impact on cancer","volume":"11","author":"Barnoud T","year":"2019","unstructured":"Barnoud T, Parris JLD, Murphy ME. Common genetic variants in the TP53 pathway and their impact on cancer. J Mol Cell Biol. 2019;11((7)):578\u2010585.","journal-title":"J Mol Cell Biol"},{"key":"e_1_3_2_269_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1017001108"},{"key":"e_1_3_2_270_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08235"},{"key":"e_1_3_2_271_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature08311"},{"issue":"7259","key":"e_1_3_2_272_2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nature08290","article-title":"The Ink4\/Arf locus is a barrier for iPS cell reprogramming","volume":"460","author":"Li H","year":"2009","unstructured":"Li H, Collado M, Villasante A, Strati K, Ortega S, Ca\u00f1amero M, et\u00a0al. The Ink4\/Arf locus is a barrier for iPS cell reprogramming. Nature. 2009;460((7259)):1136\u20101139.","journal-title":"Nature"},{"issue":"7259","key":"e_1_3_2_273_2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nature08287","article-title":"A p53\u2010mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity","volume":"460","author":"Mari\u00f3n RM","year":"2009","unstructured":"Mari\u00f3n RM, Strati K, Li H, Murga M, Blanco R, Ortega S, et\u00a0al. A p53\u2010mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature. 2009;460((7259)):1149\u20101153.","journal-title":"Nature"},{"issue":"7259","key":"e_1_3_2_274_2","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/nature08285","article-title":"Immortalization eliminates a roadblock during cellular reprogramming into iPS cells","volume":"460","author":"Utikal J","year":"2009","unstructured":"Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM, et\u00a0al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature. 2009;460((7259)):1145\u20101148.","journal-title":"Nature"},{"key":"e_1_3_2_275_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100797"},{"issue":"7","key":"e_1_3_2_276_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jmcb\/mjz071","article-title":"Mutant p53\u2010a potential player in shaping the tumor\u2010stroma crosstalk","volume":"11","author":"Stein Y","year":"2019","unstructured":"Stein Y, Aloni\u2010Grinstein R, Rotter V. Mutant p53\u2010a potential player in shaping the tumor\u2010stroma crosstalk. J Mol Cell Biol. 2019;11((7)):600\u2010604.","journal-title":"J Mol Cell Biol"},{"issue":"3","key":"e_1_3_2_277_2","first-page":"963","article-title":"Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression","volume":"9","author":"Kieser A","year":"1994","unstructured":"Kieser A, Weich HA, Brandner G, Marm\u00e9 D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 1994;9((3)):963\u2010969.","journal-title":"Oncogene"},{"key":"e_1_3_2_278_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1669"},{"issue":"8","key":"e_1_3_2_279_2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.15252\/embr.201643370","article-title":"The mutant p53\u2010ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1","volume":"18","author":"Pruszko M","year":"2017","unstructured":"Pruszko M, Milano E, Forcato M, Donzelli S, Ganci F, Di Agostino S, et\u00a0al. The mutant p53\u2010ID4 complex controls VEGFA isoforms by recruiting lncRNA MALAT1. EMBO Rep. 2017;18((8)):1331\u20101351.","journal-title":"EMBO Rep"},{"issue":"12","key":"e_1_3_2_280_2","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.18632\/oncotarget.382","article-title":"Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro\u2010invasive secretome","volume":"2","author":"Neilsen PM","year":"2011","unstructured":"Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al\u2010Ejeh F, Evdokiou A, et\u00a0al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro\u2010invasive secretome. Oncotarget. 2011;2((12)):1203\u20101217.","journal-title":"Oncotarget"},{"issue":"46","key":"e_1_3_2_281_2","doi-asserted-by":"crossref","first-page":"e10869","DOI":"10.1073\/pnas.1808314115","article-title":"p53 mutants cooperate with HIF\u20101 in transcriptional regulation of extracellular matrix components to promote tumor progression","volume":"115","author":"Amelio I","year":"2018","unstructured":"Amelio I, Mancini M, Petrova V, Cairns RA, Vikhreva P, Nicolai S, et\u00a0al. p53 mutants cooperate with HIF\u20101 in transcriptional regulation of extracellular matrix components to promote tumor progression. Proc Natl Acad Sci U S A. 2018;115((46)):e10869\u2010e10878.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_282_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061353"},{"issue":"5","key":"e_1_3_2_283_2","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.237453","article-title":"p53, cancer and the immune response","volume":"133","author":"Blagih J","year":"2020","unstructured":"Blagih J, Buck MD, Vousden KH. p53, cancer and the immune response. J Cell Sci. 2020;133((5)):jcs237453.","journal-title":"J Cell Sci"},{"key":"e_1_3_2_284_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2554"},{"key":"e_1_3_2_285_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.03.022"},{"issue":"5","key":"e_1_3_2_286_2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.molcel.2014.10.013","article-title":"Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP","volume":"56","author":"Di Minin G","year":"2014","unstructured":"Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, et\u00a0al. Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell. 2014;56((5)):617\u2010629.","journal-title":"Mol Cell"},{"issue":"19","key":"e_1_3_2_287_2","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/onc.2014.191","article-title":"Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin\u20101 receptor antagonist","volume":"34","author":"Ubertini V","year":"2015","unstructured":"Ubertini V, Norelli G, D'Arcangelo D, Gurtner A, Cesareo E, Baldari S, et\u00a0al. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin\u20101 receptor antagonist. Oncogene. 2015;34((19)):2493\u20102504.","journal-title":"Oncogene"},{"issue":"1","key":"e_1_3_2_288_2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41467-018-03224-w","article-title":"Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR\u20101246","volume":"9","author":"Cooks T","year":"2018","unstructured":"Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et\u00a0al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR\u20101246. Nat Commun. 2018;9((1)):771.","journal-title":"Nat Commun"},{"key":"e_1_3_2_289_2","doi-asserted-by":"publisher","DOI":"10.1159\/000446361"},{"key":"e_1_3_2_290_2","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjy072"},{"key":"e_1_3_2_291_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1346476"},{"issue":"42","key":"e_1_3_2_292_2","doi-asserted-by":"crossref","first-page":"39359","DOI":"10.1074\/jbc.M103429200","article-title":"Mutant p53 cooperates with ETS and selectively up\u2010regulates human MDR1 not MRP1","volume":"276","author":"Sampath J","year":"2001","unstructured":"Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, et\u00a0al. Mutant p53 cooperates with ETS and selectively up\u2010regulates human MDR1 not MRP1. J Biol Chem. 2001;276((42)):39359\u201039367.","journal-title":"J Biol Chem"},{"issue":"4","key":"e_1_3_2_293_2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/cdd.2015.133","article-title":"DNA damage\u2010induced ephrin\u2010B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53","volume":"23","author":"Alam SK","year":"2016","unstructured":"Alam SK, Yadav VK, Bajaj S, Datta A, Dutta SK, Bhattacharyya M, et\u00a0al. DNA damage\u2010induced ephrin\u2010B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53. Cell Death Differ. 2016;23((4)):707\u2010722.","journal-title":"Cell Death Differ"},{"issue":"3","key":"e_1_3_2_294_2","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.75","article-title":"Unequal prognostic potentials of p53 gain\u2010of\u2010function mutations in human cancers associate with drug\u2010metabolizing activity","volume":"5","author":"Xu J","year":"2014","unstructured":"Xu J, Wang J, Hu Y, Qian J, Xu B, Chen H, et\u00a0al. Unequal prognostic potentials of p53 gain\u2010of\u2010function mutations in human cancers associate with drug\u2010metabolizing activity. Cell Death Dis. 2014;5((3)):e1108.","journal-title":"Cell Death Dis"},{"key":"e_1_3_2_295_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.2.1438"},{"key":"e_1_3_2_296_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.04.024"},{"key":"e_1_3_2_297_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2016.04.001"},{"key":"e_1_3_2_298_2","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2011.190"},{"key":"e_1_3_2_299_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.106"},{"key":"e_1_3_2_300_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2016.11.003"},{"key":"e_1_3_2_301_2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.607149","article-title":"Mutant p53 as a Regulator and Target of","volume":"10","author":"Shi Y","year":"2020","unstructured":"Shi Y, Norberg E, Vakifahmetoglu\u2010Norberg H. Mutant p53 as a Regulator and Target of Autophagy. Front Oncol. 2020;10:607149.","journal-title":"Autophagy. Front Oncol."},{"issue":"19","key":"e_1_3_2_302_2","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.4161\/cc.7.19.6751","article-title":"Mutant p53 protein localized in the cytoplasm inhibits autophagy","volume":"7","author":"Morselli E","year":"2008","unstructured":"Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, et\u00a0al. Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle. 2008;7((19)):3056\u20103061.","journal-title":"Cell Cycle"},{"issue":"5","key":"e_1_3_2_303_2","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/0008-5472.CAN-04-3791","article-title":"Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis","volume":"65","author":"Kiaris H","year":"2005","unstructured":"Kiaris H, Chatzistamou I, Trimis G, Frangou\u2010Plemmenou M, Pafiti\u2010Kondi A, Kalofoutis A. Evidence for nonautonomous effect of p53 tumor suppressor in carcinogenesis. Cancer Res. 2005;65((5)):1627\u20101630.","journal-title":"Cancer Res"},{"key":"e_1_3_2_304_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.03.020"},{"key":"e_1_3_2_305_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17111942"},{"key":"e_1_3_2_306_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.656364"},{"key":"e_1_3_2_307_2","doi-asserted-by":"crossref","DOI":"10.1038\/srep16985","article-title":"RA\u2010XII inhibits tumour growth and metastasis in breast tumour\u2010bearing mice via reducing cell adhesion and invasion and promoting matrix degradation","volume":"5","author":"Leung HW","year":"2015","unstructured":"Leung HW, Zhao SM, Yue GG, Lee JK, Fung KP, Leung PC, et\u00a0al. RA\u2010XII inhibits tumour growth and metastasis in breast tumour\u2010bearing mice via reducing cell adhesion and invasion and promoting matrix degradation. Sci Rep. 2015;5:16985.","journal-title":"Sci Rep"},{"key":"e_1_3_2_308_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.015"},{"key":"e_1_3_2_309_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2011.12.001"},{"key":"e_1_3_2_310_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1476-4598-7-85","article-title":"Tissue inhibitor of metalloproteinases\u20104. The road less traveled","volume":"7","author":"Melendez\u2010Zajgla J","year":"2008","unstructured":"Melendez\u2010Zajgla J, Del Pozo L, Ceballos G, Maldonado V. Tissue inhibitor of metalloproteinases\u20104. The road less traveled. Mol Cancer. 2008;7:85.","journal-title":"Mol Cancer"},{"key":"e_1_3_2_311_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2016.03.046"},{"issue":"1","key":"e_1_3_2_312_2","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1038\/s41467-018-07339-y","article-title":"Mutant p53s generate pro\u2010invasive niches by influencing exosome podocalyxin levels","volume":"9","author":"Novo D","year":"2018","unstructured":"Novo D, Heath N, Mitchell L, Caligiuri G, MacFarlane A, Reijmer D, et\u00a0al. Mutant p53s generate pro\u2010invasive niches by influencing exosome podocalyxin levels. Nature Communications. 2018;9((1)):5069.","journal-title":"Nature Communications"},{"key":"e_1_3_2_313_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.15.11327"},{"key":"e_1_3_2_314_2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/den264"},{"key":"e_1_3_2_315_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"e_1_3_2_316_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021047"},{"key":"e_1_3_2_317_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1046\/j.1525-1500.1999.99021.x","article-title":"The role of cytokines and chemokines on tumor progression: A review","volume":"233","author":"Ardestani SK","year":"1999","unstructured":"Ardestani SK, Inserra P, Solkoff D, Watson RR. The role of cytokines and chemokines on tumor progression: A review. Cancer Detect Prev. 1999;233:215\u2010225.","journal-title":"Cancer Detect Prev"},{"key":"e_1_3_2_318_2","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.2001.0419"},{"key":"e_1_3_2_319_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"e_1_3_2_320_2","doi-asserted-by":"publisher","DOI":"10.1038\/35065016"},{"issue":"13","key":"e_1_3_2_321_2","first-page":"4961","article-title":"Epithelial cancer cell migration: A role for chemokine receptors?","volume":"61","author":"Scotton CJ","year":"2001","unstructured":"Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: A role for chemokine receptors? Cancer Res. 2001;61((13)):4961\u20104965.","journal-title":"Cancer Res"},{"issue":"22","key":"e_1_3_2_322_2","doi-asserted-by":"crossref","first-page":"10671","DOI":"10.1158\/0008-5472.CAN-06-2323","article-title":"p53 Attenuates cancer cell migration and invasion through repression of SDF\u20101\/CXCL12 expression in stromal fibroblasts","volume":"66","author":"Moskovits N","year":"2006","unstructured":"Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF\u20101\/CXCL12 expression in stromal fibroblasts. Cancer Res. 2006;66((22)):10671\u201010676.","journal-title":"Cancer Res"},{"key":"e_1_3_2_323_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210120"},{"key":"e_1_3_2_324_2","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgr270"},{"key":"e_1_3_2_325_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2060"},{"key":"e_1_3_2_326_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1703"},{"key":"e_1_3_2_327_2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/0470856734.ch6","article-title":"How do chemokine\/chemokine receptor activations affect tumorigenesis?","volume":"256","author":"Richmond A","year":"2004","unstructured":"Richmond A, Fan GH, Dhawan P, Yang J. How do chemokine\/chemokine receptor activations affect tumorigenesis? Novartis Found Symp. 2004;256:74\u201089.","journal-title":"Novartis Found Symp"},{"key":"e_1_3_2_328_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.03.022"},{"key":"e_1_3_2_329_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1568"},{"key":"e_1_3_2_330_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M900994200"},{"key":"e_1_3_2_331_2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1600-065X.2008.00615.x","article-title":"Is interleukin\u20101 a good or bad \u2018guy\u2019 in tumor immunobiology and immunotherapy?","volume":"222","author":"Apte RN","year":"2008","unstructured":"Apte RN, Voronov E. Is interleukin\u20101 a good or bad \u2018guy\u2019 in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222:222\u2010241.","journal-title":"Immunol Rev"},{"key":"e_1_3_2_332_2","doi-asserted-by":"publisher","DOI":"10.1038\/386194a0"},{"issue":"19","key":"e_1_3_2_333_2","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/onc.2014.191","article-title":"Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin\u20101 receptor antagonist","volume":"34","author":"Ubertini V","year":"2015","unstructured":"Ubertini V, Norelli G, D'Arcangelo D, Gurtner A, Cesareo E, Baldari S, et\u00a0al. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin\u20101 receptor antagonist. Oncogene. 2015;34((19)):2493\u20102504.","journal-title":"Oncogene"},{"key":"e_1_3_2_334_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.123.3191.309"},{"issue":"1","key":"e_1_3_2_335_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1357-4310(99)01615-9","article-title":"Causes and consequences of tumour acidity and implications for treatment","volume":"6","author":"Stubbs M","year":"2000","unstructured":"Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6((1)):15\u201019.","journal-title":"Mol Med Today"},{"key":"e_1_3_2_336_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-007-9064-0"},{"key":"e_1_3_2_337_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.05.036"},{"key":"e_1_3_2_338_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113884108"},{"key":"e_1_3_2_339_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2988"},{"key":"e_1_3_2_340_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1146"},{"key":"e_1_3_2_341_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052124"},{"key":"e_1_3_2_342_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04483"},{"key":"e_1_3_2_343_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2115"},{"key":"e_1_3_2_344_2","doi-asserted-by":"publisher","DOI":"10.1038\/44334"},{"issue":"8","key":"e_1_3_2_345_2","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1158\/0008-5472.CAN-05-2570","article-title":"Growth\u2010regulated oncogene is pivotal in thrombin\u2010induced angiogenesis","volume":"66","author":"Caunt M","year":"2006","unstructured":"Caunt M, Hu L, Tang T, Brooks PC, Ibrahim S, Karpatkin S. Growth\u2010regulated oncogene is pivotal in thrombin\u2010induced angiogenesis. Cancer Res. 2006;66((8)):4125\u20104132.","journal-title":"Cancer Res"},{"key":"e_1_3_2_346_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4843"},{"issue":"5","key":"e_1_3_2_347_2","first-page":"2256","article-title":"The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer","volume":"61","author":"Linderholm BK","year":"2001","unstructured":"Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, et\u00a0al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 2001;61((5)):2256\u20102260.","journal-title":"Cancer Res"},{"issue":"8","key":"e_1_3_2_348_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0301-472X(03)00159-0","article-title":"Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth","volume":"31","author":"Narendran A","year":"2003","unstructured":"Narendran A, Ganjavi H, Morson N, Connor A, Barlow JW, Keystone E, et\u00a0al. Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Exp Hematol. 2003;31((8)):693\u2010701.","journal-title":"Exp Hematol"},{"key":"e_1_3_2_349_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.083"},{"key":"e_1_3_2_350_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.10154"},{"issue":"1","key":"e_1_3_2_351_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.onc.1205001","article-title":"Expression of prostate specific antigen (PSA) is negatively regulated by p53","volume":"21","author":"Gurova KV","year":"2002","unstructured":"Gurova KV, Roklin OW, Krivokrysenko VI, Chumakov PM, Cohen MB, Feinstein E, et\u00a0al. Expression of prostate specific antigen (PSA) is negatively regulated by p53. Oncogene. 2002;21((1)):153\u2010157.","journal-title":"Oncogene"},{"issue":"10","key":"e_1_3_2_352_2","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1021\/pr900383g","article-title":"The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: Application to the study of p53\u2010modulated proteins secreted in lung cancer cells","volume":"8","author":"Chenau J","year":"2009","unstructured":"Chenau J, Michelland S, de Fraipont F, Josserand V, Coll JL, Favrot MC, et\u00a0al. The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: Application to the study of p53\u2010modulated proteins secreted in lung cancer cells. J Proteome Res. 2009;8((10)):4579\u20104591.","journal-title":"J Proteome Res"},{"key":"e_1_3_2_353_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay9189"},{"key":"e_1_3_2_354_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.02.027"},{"key":"e_1_3_2_355_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.09.005"},{"key":"e_1_3_2_356_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.08.012"},{"key":"e_1_3_2_357_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.09.015"},{"issue":"1","key":"e_1_3_2_358_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13059-018-1501-6","article-title":"Interaction between the microbiome and TP53 in human lung cancer","volume":"19","author":"Greathouse KL","year":"2018","unstructured":"Greathouse KL, White JR, Vargas AJ, Bliskovsky VV, Beck JA, von Muhlinen N, et\u00a0al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 2018;19((1)):123.","journal-title":"Genome Biol"},{"key":"e_1_3_2_359_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103638"},{"key":"e_1_3_2_360_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02238-5"},{"key":"e_1_3_2_361_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2541-0"},{"issue":"1","key":"e_1_3_2_362_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13062-020-00281-4","article-title":"Commensal microbes and p53 in cancer progression","volume":"15","author":"Celardo I","year":"2020","unstructured":"Celardo I, Melino G, Amelio I. Commensal microbes and p53 in cancer progression. Biol Direct. 2020;15((1)):25.","journal-title":"Biol Direct"},{"key":"e_1_3_2_363_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2008.1"},{"issue":"9","key":"e_1_3_2_364_2","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1136\/gutjnl-2019-318640","article-title":"USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis","volume":"69","author":"Costa L","year":"2020","unstructured":"Costa L, Corre S, Michel V, Le Luel K, Fernandes J, Ziveri J, et\u00a0al. USF1 defect drives p53 degradation during Helicobacter pylori infection and accelerates gastric carcinogenesis. Gut. 2020;69((9)):1582\u20101591.","journal-title":"Gut"},{"key":"e_1_3_2_365_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106200108"},{"key":"e_1_3_2_366_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3420"},{"key":"e_1_3_2_367_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00526.2009"},{"issue":"1","key":"e_1_3_2_368_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-023-01406-7","article-title":"Role of the gut microbiota in anticancer therapy: From molecular mechanisms to clinical applications","volume":"8","author":"Zhao LY","year":"2023","unstructured":"Zhao LY, Mei JX, Yu G, Lei L, Zhang WH, Liu K, et\u00a0al. Role of the gut microbiota in anticancer therapy: From molecular mechanisms to clinical applications. Signal Transduct Target Ther. 2023;8((1)):201.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_2_369_2","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2008.62"},{"key":"e_1_3_2_370_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1123"},{"key":"e_1_3_2_371_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0961"},{"issue":"3","key":"e_1_3_2_372_2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1158\/1535-7163.MCT-06-0336","article-title":"p53\u2010R273H gains new function in induction of drug resistance through down\u2010regulation of procaspase\u20103","volume":"6","author":"Wong RP","year":"2007","unstructured":"Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT. p53\u2010R273H gains new function in induction of drug resistance through down\u2010regulation of procaspase\u20103. Mol Cancer Ther. 2007;6((3)):1054\u20101061.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_2_373_2","doi-asserted-by":"publisher","DOI":"10.1080\/15384101.2019.1688951"},{"key":"e_1_3_2_374_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00078-3"},{"issue":"1","key":"e_1_3_2_375_2","doi-asserted-by":"crossref","first-page":"5321","DOI":"10.1038\/s41467-020-19173-2","article-title":"5\u2010FU promotes stemness of colorectal cancer via p53\u2010mediated WNT\/\u03b2\u2010catenin pathway activation","volume":"11","author":"Cho Y\u2010H","year":"2020","unstructured":"Cho Y\u2010H, Ro EJ, Yoon J\u2010S, Mizutani T, Kang D\u2010W, Park J\u2010C, et\u00a0al. 5\u2010FU promotes stemness of colorectal cancer via p53\u2010mediated WNT\/\u03b2\u2010catenin pathway activation. Nature Communications. 2020;11((1)):5321.","journal-title":"Nature Communications"},{"key":"e_1_3_2_376_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-01007-x"},{"key":"e_1_3_2_377_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.03.005"},{"key":"e_1_3_2_378_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206677"},{"issue":"1","key":"e_1_3_2_379_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nbt0104-3","article-title":"China approves first gene therapy","volume":"22","author":"Pearson S","year":"2004","unstructured":"Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nat Biotechnol. 2004;22((1)):3\u20104.","journal-title":"Nat Biotechnol"},{"key":"e_1_3_2_380_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc992"},{"issue":"1","key":"e_1_3_2_381_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang RX","year":"2020","unstructured":"Huang RX, Zhou PK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther. 2020;5((1)):60.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"e_1_3_2_382_2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/2211-5463.12762","article-title":"SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21CIPI, cyclin D1 and \u03b2\u2010catenin","volume":"10","author":"Lv L","year":"2020","unstructured":"Lv L, Zhou M, Zhang J, Liu F, Qi L, Zhang S, et\u00a0al. SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21CIPI, cyclin D1 and \u03b2\u2010catenin. FEBS Open Bio. 2020;10((1)):135\u2010146.","journal-title":"FEBS Open Bio"},{"key":"e_1_3_2_383_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.05.015"},{"key":"e_1_3_2_384_2","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.12659\/MSM.907256","article-title":"Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells","volume":"24","author":"Luo L","year":"2018","unstructured":"Luo L, Gao W, Wang J, Wang D, Peng X, Jia Z, et\u00a0al. Study on the Mechanism of Cell Cycle Checkpoint Kinase 2 (CHEK2) Gene Dysfunction in Chemotherapeutic Drug Resistance of Triple Negative Breast Cancer Cells. Med Sci Monit. 2018;24:3176\u20103183.","journal-title":"Med Sci Monit"},{"key":"e_1_3_2_385_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(01)00324-8"},{"key":"e_1_3_2_386_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.11.024"},{"issue":"4","key":"e_1_3_2_387_2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.celrep.2013.10.025","article-title":"A reversible gene\u2010targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo","volume":"5","author":"Morandell S","year":"2013","unstructured":"Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, et\u00a0al. A reversible gene\u2010targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep. 2013;5((4)):868\u2010877.","journal-title":"Cell Rep"},{"issue":"19","key":"e_1_3_2_388_2","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.4161\/cc.8.19.9626","article-title":"Exploiting synthetic lethal interactions for targeted cancer therapy","volume":"8","author":"Reinhardt HC","year":"2009","unstructured":"Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. 2009;8((19)):3112\u20103119.","journal-title":"Cell Cycle"},{"key":"e_1_3_2_389_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.04.014"},{"issue":"8","key":"e_1_3_2_390_2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.dnarep.2009.06.001","article-title":"Characterization of DNA damage\u2010dependent cell cycle checkpoints in a menin\u2010deficient model","volume":"8","author":"Kottemann MC","year":"2009","unstructured":"Kottemann MC, Bale AE. Characterization of DNA damage\u2010dependent cell cycle checkpoints in a menin\u2010deficient model. DNA Repair (Amst). 2009;8((8)):944\u2010952.","journal-title":"DNA Repair (Amst)"},{"key":"e_1_3_2_391_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-0888-2_2"},{"issue":"9","key":"e_1_3_2_392_2","first-page":"2036","article-title":"Absence of a radiation\u2010induced first\u2010cycle G1\u2010S arrest in p53+ human tumor cells synchronized by mitotic selection","volume":"58","author":"Nagasawa H","year":"1998","unstructured":"Nagasawa H, Keng P, Maki C, Yu Y, Little JB. Absence of a radiation\u2010induced first\u2010cycle G1\u2010S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res. 1998;58((9)):2036\u20102041.","journal-title":"Cancer Res"},{"key":"e_1_3_2_393_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M405372200"},{"key":"e_1_3_2_394_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M211027200"},{"key":"e_1_3_2_395_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2019.12.032"},{"key":"e_1_3_2_396_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng845"},{"key":"e_1_3_2_397_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-1-4939-0888-2_15","article-title":"Analyzing cell cycle checkpoints in response to ionizing radiation in mammalian cells","volume":"1170","author":"Wang B","year":"2014","unstructured":"Wang B. Analyzing cell cycle checkpoints in response to ionizing radiation in mammalian cells. Methods Mol Biol. 2014;1170:313\u2010320.","journal-title":"Methods Mol Biol"},{"key":"e_1_3_2_398_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-022-00989-y"},{"issue":"3","key":"e_1_3_2_399_2","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3892\/ol.2021.12922","article-title":"Relationship between p53 status and the bioeffect of ionizing radiation","volume":"22","author":"Kong X","year":"2021","unstructured":"Kong X, Yu D, Wang Z, Li S. Relationship between p53 status and the bioeffect of ionizing radiation. Oncol Lett. 2021;22((3)):661.","journal-title":"Oncol Lett"},{"issue":"1","key":"e_1_3_2_400_2","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang R","year":"2021","unstructured":"Huang R, Zhou PK. DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct Target Ther. 2021;6((1)):254.","journal-title":"Signal Transduct Target Ther"},{"key":"e_1_3_2_401_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111828"},{"issue":"5","key":"e_1_3_2_402_2","doi-asserted-by":"crossref","first-page":"710","DOI":"10.4161\/cc.28108","article-title":"Revisiting p53 for cancer\u2010specific chemo\u2010 and radiotherapy: Ten years after","volume":"13","author":"Beckta JM","year":"2014","unstructured":"Beckta JM, Ahmad SF, Yang H, Valerie K. Revisiting p53 for cancer\u2010specific chemo\u2010 and radiotherapy: Ten years after. Cell Cycle. 2014;13((5)):710\u2010713.","journal-title":"Cell Cycle"},{"key":"e_1_3_2_403_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0126"},{"issue":"19","key":"e_1_3_2_404_2","first-page":"4285","article-title":"Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth\u2010inhibitory potency of 123 anticancer agents","volume":"57","author":"O'Connor PM","year":"1997","unstructured":"O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et\u00a0al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth\u2010inhibitory potency of 123 anticancer agents. Cancer Res. 1997;57((19)):4285\u20104300.","journal-title":"Cancer Res"},{"issue":"6","key":"e_1_3_2_405_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00240-003-0355-9","article-title":"Radiation induces p53\u2010dependent cell apoptosis in bladder cancer cells with wild\u2010type\u2010 p53 but not in p53\u2010mutated bladder cancer cells","volume":"31","author":"Hinata N","year":"2003","unstructured":"Hinata N, Shirakawa T, Zhang Z, Matsumoto A, Fujisawa M, Okada H, et\u00a0al. Radiation induces p53\u2010dependent cell apoptosis in bladder cancer cells with wild\u2010type\u2010 p53 but not in p53\u2010mutated bladder cancer cells. Urol Res. 2003;31((6)):387\u2010396.","journal-title":"Urol Res"},{"issue":"16","key":"e_1_3_2_406_2","doi-asserted-by":"crossref","first-page":"7491","DOI":"10.1073\/pnas.89.16.7491","article-title":"Wild\u2010type p53 is a cell cycle checkpoint determinant following irradiation","volume":"89","author":"Kuerbitz SJ","year":"1992","unstructured":"Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild\u2010type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992;89((16)):7491\u20107495.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"e_1_3_2_407_2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3171\/jns.2006.105.1.111","article-title":"An accelerated senescence response to radiation in wild\u2010type p53 glioblastoma multiforme cells","volume":"105","author":"Quick QA","year":"2006","unstructured":"Quick QA, Gewirtz DA. An accelerated senescence response to radiation in wild\u2010type p53 glioblastoma multiforme cells. J Neurosurg. 2006;105((1)):111\u2010118.","journal-title":"J Neurosurg"},{"issue":"2","key":"e_1_3_2_408_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3835(99)00393-6","article-title":"p53\u2010dependent radioresistance in ovarian carcinoma cell lines","volume":"150","author":"Concin N","year":"2000","unstructured":"Concin N, Zeillinger C, Stimpfel M, Schiebel I, Tong D, Wolff U, et\u00a0al. p53\u2010dependent radioresistance in ovarian carcinoma cell lines. Cancer Lett. 2000;150((2)):191\u2010199.","journal-title":"Cancer Lett"},{"issue":"4","key":"e_1_3_2_409_2","first-page":"1557","article-title":"Low\u2010dose fractionated radiation potentiates the effects of Paclitaxel in wild\u2010type and mutant p53 head and neck tumor cell lines","volume":"9","author":"Dey S","year":"2003","unstructured":"Dey S, Spring PM, Arnold S, Valentino J, Chendil D, Regine WF, et\u00a0al. Low\u2010dose fractionated radiation potentiates the effects of Paclitaxel in wild\u2010type and mutant p53 head and neck tumor cell lines. Clin Cancer Res. 2003;9((4)):1557\u20101565.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"e_1_3_2_410_2","doi-asserted-by":"crossref","first-page":"669","DOI":"10.7150\/jca.61622","article-title":"PERK Regulates the Sensitivity of Hepatocellular Carcinoma Cells to High\u2010LET Carbon Ions via either Apoptosis or Ferroptosis","volume":"13","author":"Zheng X","year":"2022","unstructured":"Zheng X, Liu B, Liu X, Li P, Zhang P, Ye F, et\u00a0al. PERK Regulates the Sensitivity of Hepatocellular Carcinoma Cells to High\u2010LET Carbon Ions via either Apoptosis or Ferroptosis. J Cancer. 2022;13((2)):669\u2010680.","journal-title":"J Cancer"},{"key":"e_1_3_2_411_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010101)91:1<80::AID-CNCR11>3.0.CO;2-E"},{"issue":"1","key":"e_1_3_2_412_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ygyno.2015.04.015","article-title":"PI3K\/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1\u2010\u03b1\/VEGF pathway in endometrial cancer","volume":"138","author":"Miyasaka A","year":"2015","unstructured":"Miyasaka A, Oda K, Ikeda Y, Sone K, Fukuda T, Inaba K, et\u00a0al. PI3K\/mTOR pathway inhibition overcomes radioresistance via suppression of the HIF1\u2010\u03b1\/VEGF pathway in endometrial cancer. Gynecol Oncol. 2015;138((1)):174\u2010180.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"e_1_3_2_413_2","doi-asserted-by":"crossref","first-page":"5742","DOI":"10.1073\/pnas.90.12.5742","article-title":"p53 mutations increase resistance to ionizing radiation","volume":"90","author":"Lee JM","year":"1993","unstructured":"Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A. 1993;90((12)):5742\u20105746.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_414_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910610113"},{"issue":"13","key":"e_1_3_2_415_2","first-page":"3361","article-title":"Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development","volume":"54","author":"Biard DS","year":"1994","unstructured":"Biard DS, Martin M, Rhun YL, Duthu A, Lefaix JL, May E, et\u00a0al. Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res. 1994;54((13)):3361\u20103364.","journal-title":"Cancer Res"},{"issue":"5","key":"e_1_3_2_416_2","first-page":"2687","article-title":"Variations in sensitivity to ionizing radiation in relation to p53 mutation point","volume":"28","author":"Okaichi K","year":"2008","unstructured":"Okaichi K, Ide\u2010Kanematsu M, Izumi N, Morita N, Okumura Y, Ihara M. Variations in sensitivity to ionizing radiation in relation to p53 mutation point. Anticancer Res. 2008;28((5a)):2687\u20102690.","journal-title":"Anticancer Res"},{"issue":"6","key":"e_1_3_2_417_2","first-page":"2255","article-title":"Phosphorylation of p53 modifies sensitivity to ionizing radiation","volume":"31","author":"Okaichi K","year":"2011","unstructured":"Okaichi K, Nose K, Kotake T, Izumi N, Kudo T. Phosphorylation of p53 modifies sensitivity to ionizing radiation. Anticancer Res. 2011;31((6)):2255\u20102258.","journal-title":"Anticancer Res"},{"issue":"9","key":"e_1_3_2_418_2","first-page":"1793","article-title":"Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations","volume":"58","author":"Tada M","year":"1998","unstructured":"Tada M, Matsumoto R, Iggo RD, Onimaru R, Shirato H, Sawamura Y, et\u00a0al. Selective sensitivity to radiation of cerebral glioblastomas harboring p53 mutations. Cancer Res. 1998;58((9)):1793\u20101797.","journal-title":"Cancer Res"},{"issue":"2","key":"e_1_3_2_419_2","first-page":"153","article-title":"The tumor suppressor, p53, contributes to radiosensitivity of lung cancer cells by regulating autophagy and apoptosis","volume":"28","author":"Cheng G","year":"2013","unstructured":"Cheng G, Kong D, Hou X, Liang B, He M, Liang N, et\u00a0al. The tumor suppressor, p53, contributes to radiosensitivity of lung cancer cells by regulating autophagy and apoptosis. Cancer Biother Radiopharm. 2013;28((2)):153\u2010159.","journal-title":"Cancer Biother Radiopharm"},{"key":"e_1_3_2_420_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3380"},{"key":"e_1_3_2_421_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-3166"},{"key":"e_1_3_2_422_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3744"},{"issue":"6","key":"e_1_3_2_423_2","first-page":"1281","article-title":"Generation of anti\u2010p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells","volume":"5","author":"Chikamatsu K","year":"1999","unstructured":"Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, et\u00a0al. Generation of anti\u2010p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res. 1999;5((6)):1281\u20101288.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"e_1_3_2_424_2","doi-asserted-by":"crossref","first-page":"14704","DOI":"10.1073\/pnas.93.25.14704","article-title":"Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild\u2010type p53\u2010derived peptide","volume":"93","author":"R\u00f6pke M","year":"1996","unstructured":"R\u00f6pke M, Hald J, Guldberg P, Zeuthen J, N\u00f8rgaard L, Fugger L, et\u00a0al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild\u2010type p53\u2010derived peptide. Proc Natl Acad Sci U S A. 1996;93((25)):14704\u201014707.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_425_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.5.695"},{"key":"e_1_3_2_426_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2227"},{"issue":"5","key":"e_1_3_2_427_2","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1002\/ijc.27388","article-title":"Potentiation of a p53\u2010SLP vaccine by cyclophosphamide in ovarian cancer: A single\u2010arm phase II study","volume":"131","author":"Vermeij R","year":"2012","unstructured":"Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, et\u00a0al. Potentiation of a p53\u2010SLP vaccine by cyclophosphamide in ovarian cancer: A single\u2010arm phase II study. Int J Cancer. 2012;131((5)):e670\u2010e680.","journal-title":"Int J Cancer"},{"issue":"17","key":"e_1_3_2_428_2","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1158\/1078-0432.CCR-13-3361","article-title":"p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53\u2010specific CD8+ T\u2010cell responses","volume":"20","author":"Hardwick NR","year":"2014","unstructured":"Hardwick NR, Carroll M, Kaltcheva T, Qian D, Lim D, Leong L, et\u00a0al. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53\u2010specific CD8+ T\u2010cell responses. Clin Cancer Res. 2014;20((17)):4459\u20104470.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"e_1_3_2_429_2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-17-2709","article-title":"p53\u2010Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum\u2010Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy","volume":"24","author":"Hardwick NR","year":"2018","unstructured":"Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, et\u00a0al. p53\u2010Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum\u2010Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clin Cancer Res. 2018;24((6)):1315\u20101325.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"e_1_3_2_430_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1046\/j.1365-3083.2000.00668.x","article-title":"Cytotoxic T\u2010lymphocyte clones, established by stimulation with the HLA\u2010A2 binding p5365\u201073 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA\u2010A2 tumour cells overexpressing the p53 protein","volume":"51","author":"Barfoed AM","year":"2000","unstructured":"Barfoed AM, Petersen TR, Kirkin AF, Thor Straten P, Claesson MH, Zeuthen J. Cytotoxic T\u2010lymphocyte clones, established by stimulation with the HLA\u2010A2 binding p5365\u201073 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA\u2010A2 tumour cells overexpressing the p53 protein. Scand J Immunol. 2000;51((2)):128\u2010133.","journal-title":"Scand J Immunol"},{"issue":"3","key":"e_1_3_2_431_2","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia SJ","year":"2006","unstructured":"Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et\u00a0al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res. 2006;12((3) Pt 1):878\u2010887.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"e_1_3_2_432_2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14712598.2010.484801","article-title":"INGN\u2010225: A dendritic cell\u2010based p53 vaccine (Ad.p53\u2010DC) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect","volume":"10","author":"Chiappori AA","year":"2010","unstructured":"Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI. INGN\u2010225: A dendritic cell\u2010based p53 vaccine (Ad.p53\u2010DC) in small cell lung cancer: Observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther. 2010;10((6)):983\u2010991.","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_3_2_433_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2287-9"},{"issue":"2","key":"e_1_3_2_434_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10549-010-0844-9","article-title":"High immunogenic potential of p53 mRNA\u2010transfected dendritic cells in patients with primary breast cancer","volume":"125","author":"Met O","year":"2011","unstructured":"Met O, Balslev E, Flyger H, Svane IM. High immunogenic potential of p53 mRNA\u2010transfected dendritic cells in patients with primary breast cancer. Breast Cancer Res Treat. 2011;125((2)):395\u2010406.","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_3_2_435_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"e_1_3_2_436_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2355"},{"key":"e_1_3_2_437_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.083"},{"issue":"14","key":"e_1_3_2_438_2","first-page":"3257","article-title":"A mutant p53 tumor suppressor protein is a target for peptide\u2010induced CD8+ cytotoxic T\u2010cells","volume":"53","author":"Yanuck M","year":"1993","unstructured":"Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, et\u00a0al. A mutant p53 tumor suppressor protein is a target for peptide\u2010induced CD8+ cytotoxic T\u2010cells. Cancer Res. 1993;53((14)):3257\u20103261.","journal-title":"Cancer Res"},{"issue":"2","key":"e_1_3_2_439_2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1006\/jsre.1997.5058","article-title":"The use of transgenic mice to generate high affinity p53 specific cytolytic T cells","volume":"69","author":"Yu Z","year":"1997","unstructured":"Yu Z, Liu X, McCarty TM, Diamond DJ, Ellenhorn JD. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J Surg Res. 1997;69((2)):337\u2010343.","journal-title":"J Surg Res"},{"key":"e_1_3_2_440_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123791"},{"key":"e_1_3_2_441_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198443"},{"key":"e_1_3_2_442_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3247"},{"issue":"1","key":"e_1_3_2_443_2","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1038\/s41467-019-13305-z","article-title":"Targeting mutant p53\u2010expressing tumours with a T cell receptor\u2010like antibody specific for a wild\u2010type antigen","volume":"10","author":"Low L","year":"2019","unstructured":"Low L, Goh A, Koh J, Lim S, Wang CI. Targeting mutant p53\u2010expressing tumours with a T cell receptor\u2010like antibody specific for a wild\u2010type antigen. Nat Commun. 2019;10((1)):5382.","journal-title":"Nat Commun"},{"issue":"17","key":"e_1_3_2_444_2","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever MA","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et\u00a0al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15((17)):5323\u20105337.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_445_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature24462"},{"key":"e_1_3_2_446_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0573"},{"key":"e_1_3_2_447_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1874"},{"key":"e_1_3_2_448_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070724"},{"key":"e_1_3_2_449_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8697"},{"issue":"1","key":"e_1_3_2_450_2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 Regulation by p53 via miR\u201034","volume":"108","author":"Cortez MA","year":"2016","unstructured":"Cortez MA, Ivan C, Valdecanas D, Wang X, Peltier HJ, Ye Y, et\u00a0al. PDL1 Regulation by p53 via miR\u201034. J Natl Cancer Inst. 2016;108((1)):djv303.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_451_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3211"},{"key":"e_1_3_2_452_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1450-6"},{"issue":"12","key":"e_1_3_2_453_2","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1158\/2159-8290.CD-20-1741","article-title":"Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity","volume":"11","author":"Zhou X","year":"2021","unstructured":"Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, et\u00a0al. Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity. Cancer Discov. 2021;11((12)):3090\u20103105.","journal-title":"Cancer Discov"},{"issue":"23","key":"e_1_3_2_454_2","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025631118","article-title":"TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment","volume":"118","author":"Maddalena M","year":"2021","unstructured":"Maddalena M, Mallel G, Nataraj NB, Shreberk\u2010Shaked M, Hassin O, Mukherjee S, et\u00a0al. TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment. Proc Natl Acad Sci U S A. 2021;118((23)):e2025631118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"e_1_3_2_455_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s40425-019-0750-6","article-title":"MDM2 inhibitor APG\u2010115 synergizes with PD\u20101 blockade through enhancing antitumor immunity in the tumor microenvironment","volume":"7","author":"Fang DD","year":"2019","unstructured":"Fang DD, Tang Q, Kong Y, Wang Q, Gu J, Fang X, et\u00a0al. MDM2 inhibitor APG\u2010115 synergizes with PD\u20101 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer. 2019;7((1)):327.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_2_456_2","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.2021.39.15_suppl.2506","article-title":"Preliminary results of a phase II study of alrizomadlin (APG\u2010115):a novel, small\u2010molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno\u2010oncologic (I\u2010O) drugs","volume":"39","author":"Tolcher AW","year":"2021","unstructured":"Tolcher AW, Reeves JA, McKean M, Chmielowski B, Beck JT, Shaheen MF, et\u00a0al. Preliminary results of a phase II study of alrizomadlin (APG\u2010115):a novel, small\u2010molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno\u2010oncologic (I\u2010O) drugs. Journal of Clinical Oncology. 2021;39:2506.","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_3_2_457_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1484982"},{"issue":"6","key":"e_1_3_2_458_2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/s41417-021-00369-7","article-title":"Tumor suppressor immune gene therapy to reverse immunotherapy resistance","volume":"29","author":"Chada S","year":"2022","unstructured":"Chada S, Wiederhold D, Menander KB, Sellman B, Talbott M, Nemunaitis JJ, et\u00a0al. Tumor suppressor immune gene therapy to reverse immunotherapy resistance. Cancer Gene Ther. 2022;29((6)):825\u2010834.","journal-title":"Cancer Gene Ther"},{"issue":"6553","key":"e_1_3_2_459_2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/378206a0","article-title":"Rescue of embryonic lethality in Mdm2\u2010deficient mice by absence of p53","volume":"378","author":"Jones SN","year":"1995","unstructured":"Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2\u2010deficient mice by absence of p53. Nature. 1995;378((6553)):206\u2010208.","journal-title":"Nature"},{"issue":"6553","key":"e_1_3_2_460_2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/378203a0","article-title":"Rescue of early embryonic lethality in mdm2\u2010deficient mice by deletion of p53","volume":"378","author":"Montes de Oca Luna R","year":"1995","unstructured":"Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2\u2010deficient mice by deletion of p53. Nature. 1995;378((6553)):203\u2010206.","journal-title":"Nature"},{"issue":"1","key":"e_1_3_2_461_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ng714","article-title":"Rescue of embryonic lethality in Mdm4\u2010null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53","volume":"29","author":"Parant J","year":"2001","unstructured":"Parant J, Chavez\u2010Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, et\u00a0al. Rescue of embryonic lethality in Mdm4\u2010null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genetics. 2001;29((1)):92\u201095.","journal-title":"Nature Genetics"},{"key":"e_1_3_2_462_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3430"},{"issue":"15","key":"e_1_3_2_463_2","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","article-title":"The MDM2 gene amplification database","volume":"26","author":"Momand J","year":"1998","unstructured":"Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26((15)):3453\u20103459.","journal-title":"Nucleic Acids Res"},{"key":"e_1_3_2_464_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1092472"},{"key":"e_1_3_2_465_2","doi-asserted-by":"publisher","DOI":"10.1038\/375694a0"},{"key":"e_1_3_2_466_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210707"},{"key":"e_1_3_2_467_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208814"},{"key":"e_1_3_2_468_2","doi-asserted-by":"publisher","DOI":"10.1021\/ml4000657"},{"key":"e_1_3_2_469_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.05.072"},{"key":"e_1_3_2_470_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm400487c"},{"issue":"15","key":"e_1_3_2_471_2","doi-asserted-by":"crossref","first-page":"TPS7063","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7063","article-title":"MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA\u2010C in patients with relapsed or refractory acute myeloid leukemia","volume":"37","author":"Montesinos P","year":"2019","unstructured":"Montesinos P, Esteve J, Konopleva MY, Martinelli G, Ottmann OG, Rodr\u00edguez\u2010Veiga R, et\u00a0al. MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA\u2010C in patients with relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. 2019;37(((15)),_suppl):TPS7063\u2013TPS7063.","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_3_2_472_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato V","year":"2017","unstructured":"Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G. MDM2\/X inhibitors under clinical evaluation: Perspectives for the management of hematological malignancies and pediatric cancer. J Hematol Oncol. 2017;10((1)):133.","journal-title":"J Hematol Oncol"},{"key":"e_1_3_2_473_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.01.012"},{"key":"e_1_3_2_474_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.10.024"},{"key":"e_1_3_2_475_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.361"},{"issue":"36","key":"e_1_3_2_476_2","doi-asserted-by":"crossref","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled \u03b1\u2010helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53\u2010dependent cancer therapy","volume":"110","author":"Chang YS","year":"2013","unstructured":"Chang YS, Graves B, Guerlavais V, Tovar C, Packman K, To KH, et\u00a0al. Stapled \u03b1\u2010helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53\u2010dependent cancer therapy. Proc Natl Acad Sci U S A. 2013;110((36)):E3445\u2010E3454.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_477_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao3003"},{"issue":"1","key":"e_1_3_2_478_2","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1038\/s41467-022-35089-5","article-title":"PPM1D suppresses p53\u2010dependent transactivation and cell death by inhibiting the Integrated Stress Response","volume":"13","author":"Andrysik Z","year":"2022","unstructured":"Andrysik Z, Sullivan KD, Kieft JS, Espinosa JM. PPM1D suppresses p53\u2010dependent transactivation and cell death by inhibiting the Integrated Stress Response. Nature communications. 2022;13((1)):7400.","journal-title":"Nature communications"},{"issue":"6","key":"e_1_3_2_479_2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1158\/1541-7786.MCR-14-0089","article-title":"Therapeutic efficacy of p53 restoration in Mdm2\u2010overexpressing tumors","volume":"12","author":"Li Q","year":"2014","unstructured":"Li Q, Zhang Y, El\u2010Naggar AK, Xiong S, Yang P, Jackson JG, et\u00a0al. Therapeutic efficacy of p53 restoration in Mdm2\u2010overexpressing tumors. Mol Cancer Res. 2014;12((6)):901\u2010911.","journal-title":"Mol Cancer Res"},{"key":"e_1_3_2_480_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05541"},{"issue":"7","key":"e_1_3_2_481_2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cell.2006.12.007","article-title":"Modeling the therapeutic efficacy of p53 restoration in tumors","volume":"127","author":"Martins CP","year":"2006","unstructured":"Martins CP, Brown\u2010Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell. 2006;127((7)):1323\u20101334.","journal-title":"Cell"},{"key":"e_1_3_2_482_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature05529"},{"key":"e_1_3_2_483_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70474-6"},{"key":"e_1_3_2_484_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0481"},{"issue":"1","key":"e_1_3_2_485_2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2174\/1389450114666140106101412","article-title":"Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities","volume":"15","author":"Hong B","year":"2014","unstructured":"Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El\u2010Deiry WS. Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities. Curr Drug Targets. 2014;15((1)):80\u201089.","journal-title":"Curr Drug Targets"},{"key":"e_1_3_2_486_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12336"},{"key":"e_1_3_2_487_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00288"},{"key":"e_1_3_2_488_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14572"},{"key":"e_1_3_2_489_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10040635"},{"key":"e_1_3_2_490_2","doi-asserted-by":"publisher","DOI":"10.3390\/biom10020303"},{"key":"e_1_3_2_491_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fnmol.2017.00167","article-title":"Cysteines as Redox Molecular Switches and Targets of Disease","volume":"10","author":"Fra A","year":"2017","unstructured":"Fra A, Yoboue ED, Sitia R. Cysteines as Redox Molecular Switches and Targets of Disease. Front Mol Neurosci. 2017;10:167.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"e_1_3_2_492_2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1568026616666160719163839","article-title":"Targeting Non\u2010Catalytic Cysteine Residues Through Structure\u2010Guided Drug Discovery","volume":"17","author":"Hallenbeck KK","year":"2017","unstructured":"Hallenbeck KK, Turner DM, Renslo AR, Arkin MR. Targeting Non\u2010Catalytic Cysteine Residues Through Structure\u2010Guided Drug Discovery. Curr Top Med Chem. 2017;17((1)):4\u201015.","journal-title":"Curr Top Med Chem"},{"key":"e_1_3_2_493_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2008.02.004"},{"issue":"16","key":"e_1_3_2_494_2","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.4161\/cc.8.16.9382","article-title":"Mutant p53 rescue and modulation of p53 redox state","volume":"8","author":"Bykov VJ","year":"2009","unstructured":"Bykov VJ, Lambert JM, Hainaut P, Wiman KG. Mutant p53 rescue and modulation of p53 redox state. Cell Cycle. 2009;8((16)):2509\u20102517.","journal-title":"Cell Cycle"},{"key":"e_1_3_2_495_2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/ncomms2361","article-title":"Computational identification of a transiently open L1\/S3 pocket for reactivation of mutant p53","volume":"4","author":"Wassman CD","year":"2013","unstructured":"Wassman CD, Baronio R, Demir \u00d6, Wallentine BD, Chen CK, Hall LV, et\u00a0al. Computational identification of a transiently open L1\/S3 pocket for reactivation of mutant p53. Nat Commun. 2013;4:1407.","journal-title":"Nat Commun"},{"key":"e_1_3_2_496_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0302-282"},{"key":"e_1_3_2_497_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M501664200"},{"issue":"2","key":"e_1_3_2_498_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.canlet.2015.01.014","article-title":"Acute cytotoxicity of MIRA\u20101\/NSC19630, a mutant p53\u2010reactivating small molecule, against human normal and cancer cells via a caspase\u20109\u2010dependent apoptosis","volume":"359","author":"Bou\u2010Hanna C","year":"2015","unstructured":"Bou\u2010Hanna C, Jarry A, Lode L, Schmitz I, Schulze\u2010Osthoff K, Kury S, et\u00a0al. Acute cytotoxicity of MIRA\u20101\/NSC19630, a mutant p53\u2010reactivating small molecule, against human normal and cancer cells via a caspase\u20109\u2010dependent apoptosis. Cancer Lett. 2015;359((2)):211\u2010217.","journal-title":"Cancer Lett"},{"key":"e_1_3_2_499_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.77.060806.091238"},{"key":"e_1_3_2_500_2","doi-asserted-by":"publisher","DOI":"10.1110\/ps.062324206"},{"key":"e_1_3_2_501_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2015.07.006"},{"issue":"8","key":"e_1_3_2_502_2","first-page":"1739","article-title":"A structural role for metal ions in the \u201cwild\u2010type\u201d conformation of the tumor suppressor protein p53","volume":"53","author":"Hainaut P","year":"1993","unstructured":"Hainaut P, Milner J. A structural role for metal ions in the \u201cwild\u2010type\u201d conformation of the tumor suppressor protein p53. Cancer Res. 1993;53((8)):1739\u20101742.","journal-title":"Cancer Res"},{"issue":"10","key":"e_1_3_2_503_2","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4161\/cc.10.10.15642","article-title":"Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs","volume":"10","author":"Puca R","year":"2011","unstructured":"Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, et\u00a0al. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle. 2011;10((10)):1679\u20101689.","journal-title":"Cell Cycle"},{"issue":"1","key":"e_1_3_2_504_2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jnutbio.2009.12.001","article-title":"Increased level of exogenous zinc induces cytotoxicity and up\u2010regulates the expression of the ZnT\u20101 zinc transporter gene in pancreatic cancer cells","volume":"22","author":"Jayaraman AK","year":"2011","unstructured":"Jayaraman AK, Jayaraman S. Increased level of exogenous zinc induces cytotoxicity and up\u2010regulates the expression of the ZnT\u20101 zinc transporter gene in pancreatic cancer cells. J Nutr Biochem. 2011;22((1)):79\u201088.","journal-title":"J Nutr Biochem"},{"issue":"26","key":"e_1_3_2_505_2","doi-asserted-by":"crossref","first-page":"9679","DOI":"10.1039\/c3dt50513h","article-title":"Improving the bioactivity of Zn(II)\u2010curcumin based complexes","volume":"42","author":"Pucci D","year":"2013","unstructured":"Pucci D, Crispini A, Sanz Mendiguch\u00eda B, Pirillo S, Ghedini M, Morelli S, et\u00a0al. Improving the bioactivity of Zn(II)\u2010curcumin based complexes. Dalton Trans. 2013;42((26)):9679\u20109687.","journal-title":"Dalton Trans"},{"issue":"1","key":"e_1_3_2_506_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1756-9966-32-72","article-title":"A fluorescent curcumin\u2010based Zn(II)\u2010complex reactivates mutant (R175H and R273H) p53 in cancer cells","volume":"32","author":"Garufi A","year":"2013","unstructured":"Garufi A, Trisciuoglio D, Porru M, Leonetti C, Stoppacciaro A, D'Orazi V, et\u00a0al. A fluorescent curcumin\u2010based Zn(II)\u2010complex reactivates mutant (R175H and R273H) p53 in cancer cells. J Exp Clin Cancer Res. 2013;32((1)):72.","journal-title":"J Exp Clin Cancer Res"},{"key":"e_1_3_2_507_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.097550"},{"key":"e_1_3_2_508_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18112285"},{"key":"e_1_3_2_509_2","doi-asserted-by":"publisher","DOI":"10.1039\/c003915b"},{"key":"e_1_3_2_510_2","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.7b13401"},{"key":"e_1_3_2_511_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.10.012"},{"key":"e_1_3_2_512_2","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2019-0181"},{"issue":"19","key":"e_1_3_2_513_2","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1038\/sj.onc.1202041","article-title":"Human tumor\u2010derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast\u2010based assay","volume":"16","author":"Di Como CJ","year":"1998","unstructured":"Di Como CJ, Prives C. Human tumor\u2010derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast\u2010based assay. Oncogene. 1998;16((19)):2527\u20102539.","journal-title":"Oncogene"},{"issue":"15","key":"e_1_3_2_514_2","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1021\/ja301056a","article-title":"Halogen\u2010enriched fragment libraries as leads for drug rescue of mutant p53","volume":"134","author":"Wilcken R","year":"2012","unstructured":"Wilcken R, Liu X, Zimmermann MO, Rutherford TJ, Fersht AR, Joerger AC, et\u00a0al. Halogen\u2010enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc. 2012;134((15)):6810\u20106818.","journal-title":"J Am Chem Soc"},{"issue":"11","key":"e_1_3_2_515_2","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1021\/acsptsci.2c00164","article-title":"Discovery of Nanomolar\u2010Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C","volume":"5","author":"Stephenson Clarke JR","year":"2022","unstructured":"Stephenson Clarke JR, Douglas LR, Duriez PJ, Balourdas DI, Joerger AC, Khadiullina R, et\u00a0al. Discovery of Nanomolar\u2010Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C. ACS pharmacology & translational science. 2022;5((11)):1169\u20101180.","journal-title":"ACS pharmacology & translational science"},{"key":"e_1_3_2_516_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2018.04.035"},{"key":"e_1_3_2_517_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805326105"},{"key":"e_1_3_2_518_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt305"},{"key":"e_1_3_2_519_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2873"},{"issue":"6","key":"e_1_3_2_520_2","first-page":"1612","article-title":"Prion Diseases. Continuum (Minneap Minn)","volume":"21","author":"Geschwind MD","year":"2015","unstructured":"Geschwind MD. Prion Diseases. Continuum (Minneap Minn). Neuroinfectious Disease. 2015;21((6)):1612\u20101638.","journal-title":"Neuroinfectious Disease"},{"key":"e_1_3_2_521_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-061516-045104"},{"key":"e_1_3_2_522_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-061516-045115"},{"key":"e_1_3_2_523_2","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.9b13100"},{"key":"e_1_3_2_524_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.022"},{"issue":"8","key":"e_1_3_2_525_2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1073\/pnas.1500262112","article-title":"Propagation of aggregated p53: Cross\u2010reaction and coaggregation vs. seeding","volume":"112","author":"Wang G","year":"2015","unstructured":"Wang G, Fersht AR. Propagation of aggregated p53: Cross\u2010reaction and coaggregation vs. seeding. Proc Natl Acad Sci U S A. 2015;112((8)):2443\u20102448.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"e_1_3_2_526_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.546","article-title":"Gain of function of mutant p53 by coaggregation with multiple tumor suppressors","volume":"7","author":"Xu J","year":"2011","unstructured":"Xu J, Reumers J, Couceiro JR, De Smet F, Gallardo R, Rudyak S, et\u00a0al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol. 2011;7((5)):285\u2010295.","journal-title":"Nat Chem Biol"},{"key":"e_1_3_2_527_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.7b00473"},{"key":"e_1_3_2_528_2","doi-asserted-by":"publisher","DOI":"10.4161\/pri.27776"},{"issue":"33","key":"e_1_3_2_529_2","doi-asserted-by":"crossref","first-page":"28152","DOI":"10.1074\/jbc.M112.340638","article-title":"Mutant p53 aggregates into prion\u2010like amyloid oligomers and fibrils: Implications for cancer","volume":"287","author":"Ano Bom AP","year":"2012","unstructured":"Ano Bom AP, Rangel LP, Costa DC, de Oliveira GA, Sanches D, Braga CA, et\u00a0al. Mutant p53 aggregates into prion\u2010like amyloid oligomers and fibrils: Implications for cancer. J Biol Chem. 2012;287((33)):28152\u201028162.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_530_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2014.04.001"},{"issue":"2","key":"e_1_3_2_531_2","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1089\/hum.2017.218","article-title":"The First Approved Gene Therapy Product for Cancer Ad\u2010p53 (Gendicine): 12 Years in the Clinic","volume":"29","author":"Zhang WW","year":"2018","unstructured":"Zhang WW, Li L, Li D, Liu J, Li X, Li W, et\u00a0al. The First Approved Gene Therapy Product for Cancer Ad\u2010p53 (Gendicine): 12 Years in the Clinic. Hum Gene Ther. 2018;29((2)):160\u2010179.","journal-title":"Hum Gene Ther"},{"key":"e_1_3_2_532_2","doi-asserted-by":"publisher","DOI":"10.1038\/312649a0"},{"key":"e_1_3_2_533_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5286.373"},{"key":"e_1_3_2_534_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.12.9470-9478.1998"},{"key":"e_1_3_2_535_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.12.9479-9490.1998"},{"key":"e_1_3_2_536_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0558"},{"key":"e_1_3_2_537_2","doi-asserted-by":"publisher","DOI":"10.1038\/312646a0"},{"issue":"5995","key":"e_1_3_2_538_2","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/312651a0","article-title":"Cellular immortalization by a cDNA clone encoding the transformation\u2010associated phosphoprotein p53","volume":"312","author":"Jenkins JR","year":"1984","unstructured":"Jenkins JR, Rudge K, Currie GA. Cellular immortalization by a cDNA clone encoding the transformation\u2010associated phosphoprotein p53. Nature. 1984;312((5995)):651\u2010654.","journal-title":"Nature"},{"issue":"10","key":"e_1_3_2_539_2","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1002\/j.1460-2075.1992.tb05434.x","article-title":"Interaction of heat\u2010shock protein 70 with p53 translated in vitro: Evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation","volume":"11","author":"Hainaut P","year":"1992","unstructured":"Hainaut P, Milner J. Interaction of heat\u2010shock protein 70 with p53 translated in vitro: Evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. Embo J. 1992;11((10)):3513\u20103520.","journal-title":"Embo J"},{"issue":"8","key":"e_1_3_2_540_2","first-page":"2863","article-title":"Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53\u2010plus\u2010ras\u2010transformed cell lines","volume":"7","author":"Hinds PW","year":"1987","unstructured":"Hinds PW, Finlay CA, Frey AB, Levine AJ. Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53\u2010plus\u2010ras\u2010transformed cell lines. Mol Cell Biol. 1987;7((8)):2863\u20102869.","journal-title":"Mol Cell Biol"},{"issue":"44","key":"e_1_3_2_541_2","doi-asserted-by":"crossref","first-page":"40583","DOI":"10.1074\/jbc.M102817200","article-title":"Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization","volume":"276","author":"Peng Y","year":"2001","unstructured":"Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem. 2001;276((44)):40583\u201040590.","journal-title":"J Biol Chem"},{"issue":"5","key":"e_1_3_2_542_2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1541-7786.MCR-10-0534","article-title":"Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells","volume":"9","author":"Li D","year":"2011","unstructured":"Li D, Marchenko ND, Schulz R, Fischer V, Velasco\u2010Hernandez T, Talos F, et\u00a0al. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res. 2011;9((5)):577\u2010588.","journal-title":"Mol Cancer Res"},{"issue":"5","key":"e_1_3_2_543_2","first-page":"933","article-title":"Geldanamycin selectively destabilizes and conformationally alters mutated p53","volume":"11","author":"Blagosklonny MV","year":"1995","unstructured":"Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene. 1995;11((5)):933\u2010939.","journal-title":"Oncogene"},{"key":"e_1_3_2_544_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1716"},{"issue":"25","key":"e_1_3_2_545_2","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2174\/1568026616666160413141911","article-title":"Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease","volume":"16","author":"Shrestha L","year":"2016","unstructured":"Shrestha L, Bolaender A, Patel HJ, Taldone T. Heat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease. Curr Top Med Chem. 2016;16((25)):2753\u20102764.","journal-title":"Curr Top Med Chem"},{"key":"e_1_3_2_546_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605066"},{"key":"e_1_3_2_547_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1662908"},{"key":"e_1_3_2_548_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600006"},{"key":"e_1_3_2_549_2","doi-asserted-by":"publisher","DOI":"10.1038\/2057"},{"issue":"10","key":"e_1_3_2_550_2","first-page":"2666","article-title":"Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53","volume":"60","author":"Dix BR","year":"2000","unstructured":"Dix BR, O'Carroll SJ, Myers CJ, Edwards SJ, Braithwaite AW. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. Cancer Res. 2000;60((10)):2666\u20102672.","journal-title":"Cancer Res"},{"issue":"5","key":"e_1_3_2_551_2","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber K","year":"2006","unstructured":"Garber K. China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98((5)):298\u2010300.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_2_552_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1691"},{"issue":"1","key":"e_1_3_2_553_2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/s41392-020-00358-6","article-title":"Development of synthetic lethality in cancer: Molecular and cellular classification","volume":"5","author":"Li S","year":"2020","unstructured":"Li S, Topatana W, Juengpanich S, Cao J, Hu J, Zhang B, et\u00a0al. Development of synthetic lethality in cancer: Molecular and cellular classification. Signal Transduction and Targeted Therapy. 2020;5((1)):241.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"e_1_3_2_554_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aam7344"},{"key":"e_1_3_2_555_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1755-8794-6-30","article-title":"Identification of potential synthetic lethal genes to p53 using a computational biology approach","volume":"6","author":"Wang X","year":"2013","unstructured":"Wang X, Simon R. Identification of potential synthetic lethal genes to p53 using a computational biology approach. BMC Med Genomics. 2013;6:30.","journal-title":"BMC Med Genomics"},{"issue":"16","key":"e_1_3_2_556_2","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1158\/1078-0432.CCR-13-2858","article-title":"Functional kinomics identifies candidate therapeutic targets in head and neck cancer","volume":"20","author":"Moser R","year":"2014","unstructured":"Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, et\u00a0al. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014;20((16)):4274\u20104288.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"e_1_3_2_557_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.4161\/cbt.9.7.11115","article-title":"MK\u20101775, a small molecule Wee1 inhibitor, enhances anti\u2010tumor efficacy of various DNA\u2010damaging agents, including 5\u2010fluorouracil","volume":"9","author":"Hirai H","year":"2010","unstructured":"Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et\u00a0al. MK\u20101775, a small molecule Wee1 inhibitor, enhances anti\u2010tumor efficacy of various DNA\u2010damaging agents, including 5\u2010fluorouracil. Cancer Biol Ther. 2010;9((7)):514\u2010522.","journal-title":"Cancer Biol Ther"},{"key":"e_1_3_2_558_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.5991"},{"key":"e_1_3_2_559_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0381"},{"key":"e_1_3_2_560_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03167"},{"issue":"5","key":"e_1_3_2_561_2","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41578-021-00313-z","article-title":"Organ chips, organoids and the animal testing conundrum","volume":"6","author":"Horejs C","year":"2021","unstructured":"Horejs C. Organ chips, organoids and the animal testing conundrum. Nat Rev Mater. 2021;6((5)):372\u2010373.","journal-title":"Nat Rev Mater"},{"key":"e_1_3_2_562_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00325-2"},{"key":"e_1_3_2_563_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105281"},{"key":"e_1_3_2_564_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1694-1"},{"key":"e_1_3_2_565_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.005"},{"issue":"5","key":"e_1_3_2_566_2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41416-021-01444-4","article-title":"Pharmacokinetic\u2010pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies","volume":"125","author":"Bauer S","year":"2021","unstructured":"Bauer S, Demetri GD, Halilovic E, Dummer R, Meille C, Tan DSW, et\u00a0al. Pharmacokinetic\u2010pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. Br J Cancer. 2021;125((5)):687\u2010698.","journal-title":"Br J Cancer"},{"issue":"14","key":"e_1_3_2_567_2","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR\u2010246) and Azacitidine in TP53\u2010Mutant Myelodysplastic Syndromes","volume":"39","author":"Sallman DA","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia\u2010Manero G, Steensma DP, Roboz GJ, Sekeres MA, et\u00a0al. Eprenetapopt (APR\u2010246) and Azacitidine in TP53\u2010Mutant Myelodysplastic Syndromes. J Clin Oncol. 2021;39((14)):1584\u20101594.","journal-title":"J Clin Oncol"},{"issue":"14","key":"e_1_3_2_568_2","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt Plus Azacitidine in TP53\u2010Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau T","year":"2021","unstructured":"Cluzeau T, Sebert M, Rahm\u00e9 R, Cuzzubbo S, Lehmann\u2010Che J, Madelaine I, et\u00a0al. Eprenetapopt Plus Azacitidine in TP53\u2010Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des My\u00e9lodysplasies (GFM). J Clin Oncol. 2021;39((14)):1575\u20101583.","journal-title":"J Clin Oncol"},{"issue":"34","key":"e_1_3_2_569_2","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem\u2010Cell Transplantation for TP53\u2010Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"40","author":"Mishra A","year":"2022","unstructured":"Mishra A, Tamari R, DeZern AE, Byrne MT, Gooptu M, Chen YB, et\u00a0al. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem\u2010Cell Transplantation for TP53\u2010Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2022;40((34)):3985\u20103993.","journal-title":"J Clin Oncol"},{"issue":"5","key":"e_1_3_2_570_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100573","article-title":"Phase Ib study of eprenetapopt (APR\u2010246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors","volume":"7","author":"Park H","year":"2022","unstructured":"Park H, Shapiro GI, Gao X, Mahipal A, Starr J, Furqan M, et\u00a0al. Phase Ib study of eprenetapopt (APR\u2010246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors. ESMO Open. 2022;7((5)):100573.","journal-title":"ESMO Open"},{"key":"e_1_3_2_571_2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3389\/fonc.2019.00832","article-title":"Part I of GANNET53: A European Multicenter Phase I\/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High\u2010Grade, Platinum\u2010Resistant Epithelial Ovarian Cancer\u2010A Study of the GANNET53 Consortium","volume":"9","author":"Ray\u2010Coquard I","year":"2019","unstructured":"Ray\u2010Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade\u2010Lauraine E, et\u00a0al. Part I of GANNET53: A European Multicenter Phase I\/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High\u2010Grade, Platinum\u2010Resistant Epithelial Ovarian Cancer\u2010A Study of the GANNET53 Consortium. Front Oncol. 2019;9:832.","journal-title":"Front Oncol"},{"issue":"1","key":"e_1_3_2_572_2","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1038\/s41598-020-58366-z","article-title":"Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis\u2010based therapy for TP53 mutant malignancies","volume":"10","author":"Wang Y","year":"2020","unstructured":"Wang Y, Janku F, Piha\u2010Paul S, Hess K, Broaddus R, Liu L, et\u00a0al. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis\u2010based therapy for TP53 mutant malignancies. Sci Rep. 2020;10((1)):3080.","journal-title":"Sci Rep"},{"issue":"5","key":"e_1_3_2_573_2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/annonc\/mdv066","article-title":"Phase I study of pazopanib and vorinostat: A therapeutic approach for inhibiting mutant p53\u2010mediated angiogenesis and facilitating mutant p53 degradation","volume":"26","author":"Fu S","year":"2015","unstructured":"Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, et\u00a0al. Phase I study of pazopanib and vorinostat: A therapeutic approach for inhibiting mutant p53\u2010mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015;26((5)):1012\u20101018.","journal-title":"Ann Oncol"},{"issue":"1","key":"e_1_3_2_574_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/1078-0432.CCR-21-0158","article-title":"Adavosertib with Chemotherapy in Patients with Primary Platinum\u2010Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open\u2010Label, Four\u2010Arm, Phase II Study","volume":"28","author":"Moore KN","year":"2022","unstructured":"Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, et\u00a0al. Adavosertib with Chemotherapy in Patients with Primary Platinum\u2010Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open\u2010Label, Four\u2010Arm, Phase II Study. Clin Cancer Res. 2022;28((1)):36\u201044.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_2_575_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0219"},{"key":"e_1_3_2_576_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1117"},{"key":"e_1_3_2_577_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1146"},{"key":"e_1_3_2_578_2","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjz075"},{"key":"e_1_3_2_579_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203789109"},{"key":"e_1_3_2_580_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01945"},{"key":"e_1_3_2_581_2","doi-asserted-by":"publisher","DOI":"10.1002\/pro.507"},{"issue":"36","key":"e_1_3_2_582_2","doi-asserted-by":"crossref","first-page":"E5271","DOI":"10.1073\/pnas.1610421113","article-title":"2\u2010Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53\u2010compromised cells","volume":"113","author":"Bauer MR","year":"2016","unstructured":"Bauer MR, Joerger AC, Fersht AR. 2\u2010Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53\u2010compromised cells. Proc Natl Acad Sci U S A. 2016;113((36)):E5271\u2010E5280.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_583_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2018.06.013"},{"key":"e_1_3_2_584_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2015.10.052"},{"key":"e_1_3_2_585_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2015.07.016"},{"issue":"1","key":"e_1_3_2_586_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129440","article-title":"SLMP53\u20101 interacts with wild\u2010type and mutant p53 DNA\u2010binding domain and reactivates multiple hotspot mutations","volume":"1864","author":"Gomes AS","year":"2020","unstructured":"Gomes AS, Ramos H, Gomes S, Loureiro JB, Soares J, Barcherini V, et\u00a0al. SLMP53\u20101 interacts with wild\u2010type and mutant p53 DNA\u2010binding domain and reactivates multiple hotspot mutations. Biochim Biophys Acta Gen Subj. 2020;1864((1)):129440.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"4","key":"e_1_3_2_587_2","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.18632\/oncotarget.6775","article-title":"Reactivation of wild\u2010type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53\u20101, a novel anticancer small\u2010molecule","volume":"7","author":"Soares J","year":"2016","unstructured":"Soares J, Raimundo L, Pereira NA, Monteiro \u00c2, Gomes S, Bessa C, et\u00a0al. Reactivation of wild\u2010type and mutant p53 by tryptophanolderived oxazoloisoindolinone SLMP53\u20101, a novel anticancer small\u2010molecule. Oncotarget. 2016;7((4)):4326\u20104343.","journal-title":"Oncotarget"},{"issue":"8","key":"e_1_3_2_588_2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3390\/cancers11081151","article-title":"SLMP53\u20102 Restores Wild\u2010Type\u2010Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma","volume":"11","author":"Gomes S","year":"2019","unstructured":"Gomes S, Bosco B, Loureiro JB, Ramos H, Raimundo L, Soares J, et\u00a0al. SLMP53\u20102 Restores Wild\u2010Type\u2010Like Function to Mutant p53 through Hsp70: Promising Activity in Hepatocellular Carcinoma. Cancers (Basel). 2019;11((8)):1151.","journal-title":"Cancers (Basel)"},{"key":"e_1_3_2_589_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.083469"},{"key":"e_1_3_2_590_2","doi-asserted-by":"publisher","DOI":"10.1002\/mc.10038"},{"issue":"10","key":"e_1_3_2_591_2","doi-asserted-by":"crossref","first-page":"6621","DOI":"10.1021\/acs.jmedchem.0c01971","article-title":"Adamantyl Isothiocyanates as Mutant p53 Rescuing Agents and Their Structure\u2010Activity Relationships","volume":"64","author":"Burmistrov V","year":"2021","unstructured":"Burmistrov V, Saxena R, Pitushkin D, Butov GM, Chung FL, Aggarwal M. Adamantyl Isothiocyanates as Mutant p53 Rescuing Agents and Their Structure\u2010Activity Relationships. J Med Chem. 2021;64((10)):6621\u20106633.","journal-title":"J Med Chem"},{"issue":"11","key":"e_1_3_2_592_2","doi-asserted-by":"crossref","first-page":"11817","DOI":"10.18632\/oncotarget.7857","article-title":"Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides","volume":"7","author":"Tal P","year":"2016","unstructured":"Tal P, Eizenberger S, Cohen E, Goldfinger N, Pietrokovski S, Oren M, et\u00a0al. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget. 2016;7((11)):11817\u201011837.","journal-title":"Oncotarget"},{"key":"e_1_3_2_593_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114773"},{"issue":"2","key":"e_1_3_2_594_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jcb.22941","article-title":"Gambogic acid\u2010induced degradation of mutant p53 is mediated by proteasome and related to CHIP","volume":"112","author":"Wang J","year":"2011","unstructured":"Wang J, Zhao Q, Qi Q, Gu HY, Rong JJ, Mu R, et\u00a0al. Gambogic acid\u2010induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J Cell Biochem. 2011;112((2)):509\u2010519.","journal-title":"J Cell Biochem"},{"issue":"1","key":"e_1_3_2_595_2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13045-021-01169-0","article-title":"Targeting mutant p53 for cancer therapy: Direct and indirect strategies","volume":"14","author":"Hu J","year":"2021","unstructured":"Hu J, Cao J, Topatana W, Juengpanich S, Li S, Zhang B, et\u00a0al. Targeting mutant p53 for cancer therapy: Direct and indirect strategies. J Hematol Oncol. 2021;14((1)):157.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"e_1_3_2_596_2","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/0008-5472.CAN-13-3263","article-title":"Ganetespib and HSP90: Translating preclinical hypotheses into clinical promise","volume":"74","author":"Proia DA","year":"2014","unstructured":"Proia DA, Bates RC. Ganetespib and HSP90: Translating preclinical hypotheses into clinical promise. Cancer Res. 2014;74((5)):1294\u20101300.","journal-title":"Cancer Res"},{"issue":"7560","key":"e_1_3_2_597_2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nature14430","article-title":"Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment","volume":"523","author":"Alexandrova EM","year":"2015","unstructured":"Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, et\u00a0al. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015;523((7560)):352\u2010356.","journal-title":"Nature"},{"key":"e_1_3_2_598_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.08.001"},{"key":"e_1_3_2_599_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncb3427"},{"issue":"5","key":"e_1_3_2_600_2","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/carcin\/bgt032","article-title":"Degradation of NF\u2010\u03baB, p53 and other regulatory redox\u2010sensitive proteins by thiol\u2010conjugating and \u2010nitrosylating drugs in human tumor cells","volume":"34","author":"Paranjpe A","year":"2013","unstructured":"Paranjpe A, Srivenugopal KS. Degradation of NF\u2010\u03baB, p53 and other regulatory redox\u2010sensitive proteins by thiol\u2010conjugating and \u2010nitrosylating drugs in human tumor cells. Carcinogenesis. 2013;34((5)):990\u20101000.","journal-title":"Carcinogenesis"},{"key":"e_1_3_2_601_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153187","article-title":"Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis","volume":"68","author":"Wang YL","year":"2020","unstructured":"Wang YL, Wu W, Su YN, Ai ZP, Mou HC, Wan LS, et\u00a0al. Buxus alkaloid compound destabilizes mutant p53 through inhibition of the HSF1 chaperone axis. Phytomedicine. 2020;68:153187.","journal-title":"Phytomedicine"},{"key":"e_1_3_2_602_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1079"},{"issue":"15","key":"e_1_3_2_603_2","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1101\/gad.220897.113","article-title":"Chaperone\u2010mediated autophagy degrades mutant p53","volume":"27","author":"Vakifahmetoglu\u2010Norberg H","year":"2013","unstructured":"Vakifahmetoglu\u2010Norberg H, Kim M, Xia HG, Iwanicki MP, Ofengeim D, Coloff JL, et\u00a0al. Chaperone\u2010mediated autophagy degrades mutant p53. Genes Dev. 2013;27((15)):1718\u20101730.","journal-title":"Genes Dev"},{"issue":"17","key":"e_1_3_2_604_2","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1073\/pnas.0802091105","article-title":"Small\u2010molecule RETRA suppresses mutant p53\u2010bearing cancer cells through a p73\u2010dependent salvage pathway","volume":"105","author":"Kravchenko JE","year":"2008","unstructured":"Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, et\u00a0al. Small\u2010molecule RETRA suppresses mutant p53\u2010bearing cancer cells through a p73\u2010dependent salvage pathway. Proc Natl Acad Sci U S A. 2008;105((17)):6302\u20106307.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"e_1_3_2_605_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0955"},{"key":"e_1_3_2_606_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4236"},{"key":"e_1_3_2_607_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coisb.2017.04.007"},{"key":"e_1_3_2_608_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4552"}],"container-title":["Cancer Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1002\/cac2.12520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:47:01Z","timestamp":1773823621000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1002\/cac2.12520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,4]]},"references-count":607,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/cac2.12520"],"URL":"https:\/\/doi.org\/10.1002\/cac2.12520","relation":{},"ISSN":["2523-3548"],"issn-type":[{"value":"2523-3548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,4]]},"assertion":[{"value":"2023-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}